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ABSTRACT 
 
CD8+ T-CELL RESPONSES IN A TH2-POLARIZED INFLAMMATORY SETTING 
Vanessa C. Kurzweil 
Paula M. Oliver 
A variety of external factors can affect the activation status, effector function, and 
memory differentiation of T cells. Such factors include resident microbiota and the 
cytokine milieu produced in a host. Loss of tolerance to commensal bacteria and excess 
inflammatory cytokines such as IL-4 have been implicated in the pathogenesis of many 
diseases, including inflammatory bowel disease (IBD) and allergy. Although these 
diseases are traditionally associated with CD4+ T cells, it is increasingly appreciated that 
CD8+ T cells in these settings may either contribute to or reduce pathology. This work 
explores the influence of various factors on CD8+ T-cell responses in an inflammatory 
setting, mice deficient in Nedd4-family interacting protein 1 (Ndfip1). Ndfip1 restricts IL-4 
production in CD4+ T cells by facilitating degradation of the transcription factor JunB. 
Ndfip1-deficient CD4+ T cells have increased JunB levels and consequently overproduce 
IL-4. This excess IL-4 impairs Th17 and iTreg differentiation. Mice lacking Ndfip1 
develop severe TH2-mediated inflammation at sites of environmental antigen exposure, 
including skin, GI tract, and lung, and develop IBD-like symptoms. We first tested the 
role of bacterial antigens in triggering this phenotype by treating mice lacking Ndfip1 in T 
cells with a cocktail of antibiotics to deplete intestinal bacteria. We then analyzed T cells 
for activation markers and examined tissues for signs of inflammation in the GI tract. 
Next, we analyzed whether exposure to the high levels of IL-4 in Ndfip1KO mice affects 
CD8+ T cell differentiation. We concluded that IL-4, but not intestinal bacteria, is required 
for the increase in activated/memory phenotype CD8+ T cells observed in Ndfip1KO 
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mice. These findings add to the growing body of literature describing the importance of 
extrinsic cytokines to the development of memory-phenotype CD8+ T cells, and raise the 
possibility that such cells may be clinically relevant in diseases which are characterized 
by local increases in IL-4. 
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CHAPTER 1: INTRODUCTION 
 
Preface 
Blood is a suspension of cells and proteins in liquid. When left at room temperature, the 
predominant cell type in blood, erythrocytes, slowly sink and separate from the liquid 
plasma. In many inflammatory disease states, however, the speed at which the 
erythrocytes sink is significantly increased, so that up to four layers become discernible 
when blood is kept in a clear container: a dark bottom layer filled with dying erythrocytes, 
which changes to bright red further up the vessel, closer to the oxygen; a cloudy, greyish 
layer containing white blood cells, platelets, and fibrin; and the translucent plasma layer. 
Pathologist Robin Fåhræus, who helped establish the modern erythrocyte sedimentation 
rate diagnostic test, suggested that this property of blood inspired the ancient Greek 
theory of the four humors – a theory which influenced Western and Islamic medicine for 
two millennia (1, 2). In this view, the layers of separated blood correspond to the 
humors: black bile, (true) blood, phlegm, and yellow bile. Whether or not the humoral 
theory of disease actually originated with the observation of drawn blood, the 
appearance of “decaying blood” was certainly used as proof of the existence of humors 
(3).  
According to humoral theory, all four humors exist in a healthy person in a natural 
balance. The humors were influenced by one’s natural disposition and by external 
factors such as the weather, the time of day, and one’s diet. An imbalance in one or 
more humors led to illness, and treatment therefore aimed to restore this balance (2, 3). 
Although the four humors have taken their place alongside the ether, homunculus, flat 
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earth, and other historical hypotheses, the guiding principles of humoral theory are 
applicable to modern physiology, and especially to the immune system.  
Improper Stimuli and Imbalance: Allergic Diseases 
Humoral theory identified many factors that could affect the body’s humors, and many of 
these factors have been shown by modern science to influence components of the 
immune system. The foods we eat, our activity level, and the ambient temperature can 
all alter immune function, as do factors the ancients did not conceive of, such as 
commensal bacteria (4–8). Moreover, it was believed that such factors could influence 
individuals differently based on one’s intrinsic susceptibilities and current disease state 
(3). This insight is still accurate. The immune response to a given antigen can vary 
greatly among individuals, though of course it has more to do with genetics and 
biochemistry than with black bile and phlegm.  
One of the main functions of the immune system is to fight infections by foreign 
pathogens such as viruses, bacteria, and parasites. However, in some individuals, the 
immune system mounts chronic, pathological responses to self-antigens and harmless 
foreign antigens, resulting in autoimmune and allergic diseases, respectively. Such 
diseases include food allergies, skin allergies, intestinal bowel diseases (IBD), and 
asthma. These diseases cause significant morbidity; in the United States alone, asthma 
accounts for over 2 million ED visits annually (9).  
The mechanisms that drive allergic inflammation can be complex, involving numerous 
parts of the immune system. One common pathway which is active in many allergic 
diseases is the Type I hypersensitivity response. This involves cytokines produced by 
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Th2-polarized CD4+ T cells, especially IL-4. IL-4 can induce B cells to class switch the 
type of antibody they produce to immunoglobulin E (IgE), which binds to receptors on 
mast cells (10, 11). Subsequent encounter with the allergen can cross-link IgE bound to 
the surface of mast cells and induce cell degranulation, leading to release of histamine 
and other inflammatory mediators (12). Histamine signaling through its various receptors 
is responsible for many symptoms classically associated with allergies, such as itching, 
skin rashes, or runny nose (13). Another Th2 cytokine, IL-5, also contributes to allergic 
responses by inducing the maturation and activation of eosinophils. Activated 
eosinophils contribute to allergic pathology in a number of ways, for example by 
degranulating to release cytotoxic proteins that can cause direct tissue damage as well 
as induce further mast cell degranulation (14, 15).  
T cells can also play a more direct role in allergic and autoimmune pathology. For 
example, in Type IV hypersensitivity reactions, which are common in many cases of 
allergic dermatitis, CD8+ T cells release cytolytic proteins that cause tissue damage. 
CD4+ and CD8+ T cells also release cytokines such as IL-2 and IFNγ that contribute to 
the recruitment and activation of other immune cells, leading to increased localized 
inflammation (16–18). 
The ancient intuition that environmental factors can have different effects on the health 
of different individuals is thus exemplified by the myriad agents that can affect the 
immune system, as well as by the fact that some people mount harmful immune 
responses to otherwise harmless antigens. Such allergic responses are characterized by 
an imbalance not of the four humors, but within one humor; that is, within the white blood 
cells of the “phlegm.” Excess production of certain cytokines, too many of certain T-cell 
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subsets or not enough of others, the relative frequencies of different antibody isotypes – 
all of these alterations to the immune system can contribute to the development of 
disease. Some of these agents, and their associated diseases, have been studied more 
extensively with a focus on CD4+ T cells rather than CD8+ T cells. Such diseases include 
inflammatory bowel disease (IBD) and allergy. This work will focus largely on the 
influence of external factors on CD8+ T-cell responses in a setting that exhibits 
characteristics of both IBD and allergic responses, mice deficient in Nedd4-family 
interacting protein 1 (Ndfip1). The remainder of the introduction will therefore provide 
background information on CD8+ T cells before introducing Ndfip1 and the Ndfip1KO 
mouse. 
Activation and Differentiation of CD8+ T cells 
T cell responses to primary infections 
Naïve T cells are mature, antigen-inexperienced lymphocytes that are found mostly in 
lymph nodes and, to a lesser extent, spleen. In these secondary lymphoid tissues, naïve 
cells encounter antigen-presenting cells (APCs) which display foreign and self peptides 
on their surfaces in complex with major histocompatibility molecules (MHC). T-cell 
receptors (TCRs) on naïve peripheral T cells bind with low affinity to most self-
peptide/MHC complexes but interact strongly with particular exogenous-peptide/MHC 
combinations specific to each TCR. Ligation of the TCR and CD4 or CD8 coreceptor by 
peptide-MHC complexes is often referred to as “signal 1” of T-cell activation. Signal 1 
initiates a signaling cascade that is augmented by ligation of costimulatory receptors, 
such as CD28, by ligands such as B7.1 that are primarily expressed on activated APCs. 
This costimulation serves as “signal 2,” and together with signal 1 induces the activation 
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and proliferation of naïve T cells. APCs need only interact with T cells for a few hours to 
prime T cells to proliferate, although longer periods of stimulation are required for 
optimal expansion (19–23).  
After activation, naïve CD8+ T cells proliferate and differentiate to effector cells which 
produce cytokines such as IFNγ and TNFα and can induce apoptosis in other cells. This 
cytotoxic function can be mediated by release of lytic molecules like perforin and 
granzymes as well as by ligation of the receptor Fas on the target cell by Fas ligand 
expressed on the T cell. Although initial activation of CD8+ T cells requires only signals 1 
and 2, for full effector differentiation naïve cells also require “signal 3.” This can be 
provided by inflammatory cytokines including IL-12 and Type I interferon. In the absence 
of these cytokines, fewer effector cells are generated and the resulting effectors have 
reduced expression of granzyme B and thus impaired cytolytic capacity (24–27). 
After the initial response to a pathogen, the effector pool contracts as most cells die by 
apoptosis. The remaining cells constitute a population of memory T cells specific to the 
original antigen. Because they exist at a higher frequency than antigen-specific naïve 
cells and because memory CD8+ T cells produce effector cytokines and cytolytic 
molecules faster than naïve cells, memory cells play a vital role in enhancing the 
immune response upon secondary encounter with a pathogen (28, 29). 
Heterogeneity in the effector CD8+ T-cell pool 
During a primary immune response, the effector CD8+ T cell population quickly diverges 
into a heterologous mix of cells with varying potential to become memory cells (30). On 
one end of the spectrum are short-lived effector cells (SLECs), most of which die soon 
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after pathogen clearance. On the other end are memory-precursor effector cells 
(MPECs), which are more likely to become long-lived, self-renewing memory T cells. 
The relative numbers of SLECs and MPECs that arise vary greatly depending on the 
type of infection. So, too, does the surface phenotype of the different effector subsets, 
although enough similarities exist in the effector responses to acute infections that 
certain markers are commonly used to distinguish SLECs and MPECs. Killer cell lectin-
like receptor G1 (KLRG1) is strongly associated with cells that are more terminally 
differentiated and thus is more highly expressed on SLECs than MPECs (31–34). In 
contrast, expression of the IL-7R alpha chain (CD127) tends to favor cell survival by 
enhancing responsiveness to IL-7, and is usually more highly expressed on MPECs than 
on SLECs (30, 35). Although all effector CD8+ T cells typically express both T-bet and 
Eomesodermin (Eomes), transcription factors that control a variety of CD8+ T cell 
effector functions, SLECs express higher levels of T-bet while MPECs express more 
Eomes (32, 36–38). Additionally, the transcription factors Blimp-1 and Bcl6 are 
reciprocally expressed in effector subsets. Blimp-1 drives differentiation of CD8+ T cells 
to cytotoxic, terminally differentiated effectors, while Bcl6 enhances proliferative capacity 
and memory differentiation. Blimp-1 and Bcl6 can each repress expression of the other, 
so it is unsurprising that SLECs tend to express more Blimp-1 while MPECs express 
more Bcl6 (39–42). Other markers that can help distinguish between effector subsets 
have also been identified; for example, expression of CD57 or of certain isoforms of 
CD43 is often associated with terminally differentiated cells, while memory precursors 
may express high levels of costimulatory receptors CD27 and CD28 (43–46). However, 
these markers are typically most useful for identifying effector subsets in concert with 
KLRG1 and CD127. 
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How does heterogeneity arise among effector cells? 
Although the existence of effector subsets following many primary immune responses is 
well-established, it is less clear how these subsets arise. Several models can account for 
the observed heterogeneity in effector responses, and no consensus has yet emerged 
as to which is most accurate – or, indeed, whether a single model applies in all cases. 
However, recently some of the most controversial questions have been essentially 
settled. As an example, for several years the possibility that heterogeneity actually exists 
at the level of naïve cells, such that certain naïve cells are destined to become either 
terminal effectors or memory cells, could not be discounted. However, multiple studies 
have now reported that individual naïve CD8+ T cells can give rise to all of the effector 
and memory populations typically observed in infection models (47–49). Moreover, many 
of the signals that contribute to effector versus memory differentiation have been 
identified. For example, high levels of inflammatory cytokines such as IL-12, IFNα, and 
even IL-2 can drive an expansion of effector CD8+ T cells (32, 50, 51). As the subject of 
effector and memory CD8+ T-cell differentiation has been reviewed extensively (52–55), 
I will here give an overview of some prominent theories in the context of recent studies.  
First, the divergent lineage model holds that effector versus memory fate is fixed early in 
the immune response based on different initial signals. Several lines of evidence support 
this. Polarization of several signaling proteins can be observed in naïve cells upon 
sustained contacted with an APC (56). The proximal side of the T cell, where the 
immunological synapse forms as the TCR interacts with MHC molecules on the APC, 
accumulates higher levels of CD8, LFA-1 and the IFNγ receptor than the distal end, and 
this polarization is maintained through mitosis. The “proximal” daughter cell displays a 
more activated phenotype than the “distal” daughter cell and also expresses more T-bet 
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protein and granzyme B mRNA, leading many to speculate that proximal progeny 
become effector cells while distal progeny become memory cells. T-cell polarization and 
resulting asymmetric division requires a threshold affinity between the TCR and 
peptide/MHC complex, and high affinity interactions are associated with more stable 
synapses and an enhanced effector response (57). Additionally, mutations in the TCR β 
transmembrane domain that reduce TCR polarization at the immunological synapse lead 
to impaired memory cell development, indicating that polarization during T-cell 
stimulation affects the downstream phenotype of daughter cells (58). Finally, another set 
of experiments suggests that lineage commitment occurs early, if not at the first cell 
division. These experiments examine early effector cells (EECs), which arise before 
SLECs and MPECs can be distinguished and are uniformly KLRG1lo CD127lo. Obar et 
al. (59) sorted EECs, MPECs, and SLECs expressing the OTI transgene 5 days after 
infection with recombinant vesicular stomatitis virus expressing ovalbumin (VSV-OVA), 
then transferred these to infection-matched recipients. Two days after transfer, EECs 
had given rise both to MPECs and SLECs, as well as more EECs. Transfer of MPECs 
resulted in large populations of both EECs and MPECs, with a very small percentage 
differentiating to SLECs. Transferred SLECs remained SLECs, and, unlike transferred 
MPECs, could no longer be detected 35 days after transfer.  Thus, while EECs are 
highly plastic, once they acquire a SLEC or MPEC phenotype their fate may be 
essentially fixed.  
The findings of Obar et al., however, may also support the model of decreasing 
potential. In this model, differentiation of T cells is fairly linear; cells initially acquire a 
memory-like phenotype and, upon repeated stimulation by antigen and cytokines, 
progressively lose memory potential and acquire a more effector-like phenotype. This is 
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consistent with studies that found that cells which underwent the most cell divisions were 
more likely to be KLRG1hi and curtailing antigen exposure enhanced memory cell 
formation (34, 60, 61).  Certainly, this model better accounts for recent data showing that 
individual naïve T cells with identical TCRs give rise to vastly differing percentages of 
memory precursor cells, with memory precursors being inversely correlated to total 
proliferation (49, 62). Interestingly, computational modeling of the results of one recent 
single-cell transfer study indicated that the data could be best explained a model in 
which 90% of responding T cells differentiated according to the decreasing potential 
model, while the remaining 10% underwent asymmetric division (62). A similar model, 
strength-of-signal, also suggests that the antigen and cytokine stimulation a cell receives 
determines it memory versus effector fate, but holds that these lineages diverge early in 
infection. Supporting this is the observation that, three days after infection with LCMV, 
responding CD8+ T cells are a mix of CD25hi and CD25lo cells and the CD25hi cells, 
which are more responsive to IL-2, preferentially develop into effector cells even when 
transferred into uninfected hosts (63).  
A combination of the latter two models, in which SLECs and MPECs begin to diverge 
early during infection but which allows for later conversion of MPECs to SLECs based on 
high continuing stimulation, may fit best with our current understanding of T-cell 
differentiation. Although asymmetric division alone cannot account for experimental 
observations, it can be incorporated into this model by viewing asymmetric division as 
one of several factors that contribute to “strength of signal,” predisposing one daughter 
cell to an effector fate after the progenitor experiences especially strong TCR stimulation 
by an APC.   
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Characteristics of CD8+ Memory T cells 
As previously mentioned, memory cells in general differ from naïve cells in their 
increased frequency per specific antigen and their more rapid secretion of effector 
cytokines and cytolytic molecules. When compared to effector cells, memory CD8+ T 
cells are better able to produce IL-2 and are longer-lived, capable of homeostatic self-
renewal; however, effector cells are more cytolytic and better able to traffic to peripheral 
tissues.  
These generalities are useful for characterizing a phenotype as more “effector-like” or 
“memory-like,” but in reality the memory population exhibits as much heterogeneity as 
does the effector population. Memory CD8+ T cells can be divided most simply into 
“central memory” and “effector memory” subtypes, both of which can be found in spleen 
and blood (64). Central memory T cells express CCR7 and high levels of CD62L, which 
allow them to circulate through lymph nodes. Upon stimulation, these cells can rapidly 
proliferate and produce IL-2 (65, 66). Effector memory cells express low levels of CCR7 
and CD62L and preferentially localize to non-lymphoid organs. These cells are less able 
to proliferate and produce IL-2 than central memory cells but have higher cytolytic 
capacity (66–68). However, these descriptions of central and effector memory cells are 
highly simplified; actual memory cells often form a spectrum of phenotypes based on 
functional properties and surface markers (45, 69–73). 
The origins of different memory subsets are as controversial as the debate surrounding 
effector differentiation, and the two subjects are intrinsically linked: The same factors 
that influence effector versus memory fate also tend to influence the balance of memory 
subsets (61, 65, 74–76). In fact, the division between central and effector memory cells 
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may arise among the MPEC population early in the response to acute infection (77). 
Since CD62L expression is inversely linked to proliferation, this may reflect progressive 
differentiation toward an effector phenotype as a cell receives more/stronger stimulatory 
signals (78). Regardless of their initial origins, upon secondary challenge central 
memory cells can give rise to effector memory cells (64, 69, 79). Some effector memory 
cells may also convert to the central memory phenotype, but this appears to require a 
relatively high frequency of naïve precursors; the endogenous frequency of many 
antigen-specific cells is low and these cells generate more stable effector-memory 
populations (80–82). The central and effector memory subsets may play different roles in 
different infections, with central memory cells better able to target pathogens that 
replicate in lymphoid organs and effector memory cells rapidly responding to infections 
in peripheral tissues (65, 83). 
Ndfip1 
The model system in which we will examine the influence of various stimuli on CD8+ T 
cells is the Ndfip1KO mouse. To understand why we are interested in this system, it is 
first necessary to explain the role of Ndfip1 in T cells as we understand it. To do that, we 
will briefly review the biology of ubiquitylation. 
Ubiquitylation of a target protein requires three types of enzymes, termed E1, E2, and 
E3.  E3 enzymes, called ubiquitin ligases, bind to target proteins either directly or 
through an adapter, thus conferring specificity to the reaction.  HECT-type E3 ubiquitin 
ligases contain a catalytic HECT domain and directly transfer ubiquitin to the target 
protein.  Among the HECT-type E3 ubiquitin ligases, there is a family that exhibits a high 
degree of homology, called the Nedd4 family.  Nedd4-family ligases play important roles 
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in various pathways, including in T cells (84–86). The nine mammalian Nedd4-family E3 
ubiquitin ligases all contain, in addition to a conserved HECT domain, a variable number 
of WW domains, which bind to PPXY (PY) and other motifs (87). Ndfip1 is a 
transmembrane protein which contains three PY motifs, and was originally identified in a 
screen for proteins which bind to Nedd4’s WW domains (88).  While Ndfip1 has not been 
characterized in CD8+ T cells, in CD4+ T cells, Ndfip1 binds to the Nedd4-family E3 
ligase Itch and promotes Itch-mediated ubiquitylation of the transcription factor JunB 
(89).  Following ubiquitylation, JunB is degraded, and thus is prevented from binding to 
the IL-4 promoter to enhance IL-4 transcription.  Consequently, CD4+ T cells from both 
Itchy mice, which have a chromosomal inversion that ablates Itch expression (90), and 
Ndfip1-/- mice have elevated JunB levels and produce high amounts of IL-4 (Figure 1).   
Both Itchy and Ndfip1-/- mice develop spontaneous, lethal inflammatory disease of the 
digestive tract, skin, and lung.  This phenotype is dependent on cells of the adaptive 
immune system, as Ndfip1-/- Rag1-/- mice do not develop disease.  Ndfip1KO CD4+ T 
cells transferred into Rag1-/- mice are sufficient to induce inflammation; however, 
whether CD8+ T cells contribute to the pathology in Ndfip1-/- mice, or are capable of 
inducing a distinct inflammatory response in the absence of Th2-polarized CD4+ T cells, 
is unknown. 
 
Because Ndfip1KO mice develop symptoms consistent with both IBD and allergy, it is a 
useful system to explore the role of factors that drive these diseases in CD8+ T cell 
activation and differentiation. Therefore, this dissertation will explore the inflammatory 
stimuli affecting Ndfip1KO T cells in two different contexts. First, Chapter 2 explores the 
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role of intestinal bacteria in driving T-cell activation and GI pathology in Ndfip1-deficient 
mice. Second, Chapter 3 examines how the high levels of IL-4 in Ndfip1KO mice affect 
the phenotype of CD8+ T cells.  
Figure 1: Ndfip1 cooperates with Itch to induce JunB degradation 
Schematic of Ndfip1 (A) and the E3 ubiquitin ligase Itch (B). (C) In Th2 CD4+ T cells, JunB binds to the IL-4 
promoter and enhances IL-4 transcription. (D) In Th1 cells, Ndfip1 binds to Itch, allowing Itch to ubiquitylate 
JunB. Ubiquitylated JunB is targeted for degradation and IL-4 transcription is inhibited. 
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CHAPTER 2: GASTROINTESTINALMICROBIOTA DO NOT SIGNIFICANTLY 
CONTRIBUTE TO T-CELL ACTIVATION OR GI INFLAMMATION IN NDFIP1-
CKO MICE1 
 
Introduction 
Bacteria in the mammalian gut play a crucial role in host homeostasis, aid digestion, 
provide competitive barriers to pathogen invasion, and contribute to immune system 
development (91). While the intestinal immune system is capable of mounting a rapid 
effector response to pathogenic bacteria, it is tolerant toward gastrointestinal microflora 
and does not normally mount an immune response against bacteria-derived antigens 
(92). A loss of tolerance to gastrointestinal bacteria has been implicated in the 
pathogenesis of many mucosal diseases, including inflammatory bowel disease 
(IBD)(23, 89, 92, 93).  
It was recently shown that mice deficient in Nedd4-family interacting protein-1 (Ndfip1) 
develop IBD-like symptoms (93). Ndfip1 is an adaptor for E3 ubiquitin ligases of the 
Nedd4-family, including Itch. Itch can promote ubiquitin-mediated degradation of various 
signaling proteins, thereby suppressing T cell activation and inflammation (23). Ndfip1 
has been shown to promote Itch function in vivo. For example, Ndfip1 promotes Itch 
ubiquitylation and subsequent degradation of JunB, a transcription factor that increases 
production of proinflammatory TH2 cytokines interleukin (IL)-4 and IL-5.  In the absence 
of Ndfip1, JunB accumulates and promotes TH2 cytokine transcription (89).  Mice lacking 
Ndfip1 develop severe TH2-mediated inflammation at sites of environmental antigen 
                                                
1 A version of this chapter was published in PLoS One (2012) 7(4): e34478 with the following 
authors: Vanessa Kurzweil, Amy Tarangelo, and Paula Oliver. 
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exposure, including skin, GI tract, and lung. GI inflammation in Ndfip1-/- mice is 
preceded by aberrant activation of CD4+ and CD8+ T cells and increased IL-5 
production, followed by recruitment of eosinophils into the GI tissue (94). Transfer of 
Ndfip1-/- CD4+ T cells is sufficient to induce GI inflammation in Rag1-/- mice (94). 
Additionally, mice lacking Ndfip1 only in T cells (referred to here as Ndfip1 cKO mice) 
develop GI tract symptoms similar to those observed in Ndfip1-/- mice (94). These 
observations suggest that, in the absence of Ndfip1, aberrant T-cell responses drive 
eosinophil recruitment and inflammation in the GI tract. 
The localization of inflammation in Ndfip1-/- mice to sites of environmental antigen 
exposure suggests loss of tolerance to environmental antigens.  Thus, we hypothesized 
that GI inflammation in Ndfip1-/- mice is caused by an inappropriate T-cell response to 
gastrointestinal microbiota. In several genetic models of IBD, depletion of intestinal 
bacteria by oral antibiotic treatment greatly reduces intestinal inflammation (95–97). We 
therefore tested the role of bacterial antigens in triggering the Ndip1-/- phenotype by 
treating Ndfip1 cKO mice with a cocktail of antibiotics and subsequently analyzing 
tissues for signs of inflammation in the GI tract. 
Results 
Ndfip1-cKO mice Display T-cell Activation and GI Inflammation 
Ndfip1-deficient mice develop a severe inflammatory disease by 6 weeks of age. 
However, the precise age of disease onset in mice lacking Ndfip1 only in T lineage cells 
was unknown. We sought to characterize Ndfip1-cKO mice at 3 and 5 weeks of age by 
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testing for T cell activation in the spleen as well as T cell and eosinophil infiltration of the 
small bowel and esophagus.   
Histological sections of esophagus showed increased inflammation and hypertrophy of 
the esophageal epithelium of Ndfip1-cKO mice at 5 weeks of age. However, no 
discernible difference between control and Ndfip1-cKO mice was observed at 3 weeks 
(Figure 2 A). Flow cytometric analysis of cells isolated from the esophagus showed an 
increased percentage of Siglec-F+ cells in Ndfip1-cKO mice by 5 weeks of age. In 
contrast, the percentage of eosinophils in the esophagus of 3 week old Ndfip1-cKO mice 
was not as profound (Figure 2 B). Similarly, an increase in the percentages of 
eosinophils in the small bowel of Ndfip1 cKOs was observed at 5 weeks, but this was not 
as evident at 3 weeks-of-age (Figure 2 C). Spleens of Ndfip1 cKO mice are typically 
enlarged 2-3 fold compared with wild-type littermates. Average total spleen cellularity 
was 101x106 cells for 3-week-old Ndfip1 cKO animals compared to 40 x106 for 3 –week-
old controls. By five weeks of age the total numbers of cells isolated from the spleens of 
Ndfip1-cKO mice had increased further, to an average of 124 x106. Because of this 
increase in cellularity, we compared differences in activation of splenic T cells in 3 and 5 
week old mice. As shown previously, T cells lacking Ndfip1 are more likely to have a 
previously activated phenotype, characterized by increased levels of CD44, than control 
T cells. Interestingly, flow cytometry analysis showed a similar increase in CD4+ T cell 
activation at both 3 and 5 weeks of age (Figure 2 D). Similar results were observed in 
CD8+ T cells isolated from the spleen (data not shown).  
We have shown previously that in Ndfip1-/- Rag1-/- mice that contain T cells specific for 
an ovalbumin peptide that is not expressed in mice (OTII), T cells maintain a naïve 
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phenotype (94). Thus, T cells lacking Ndfip1 must be exposed to antigen(s) to acquire 
an activated phenotype. Taken together, these data suggest that T cells lacking Ndfip1 
become activated by antigens and then migrate into the GI tract where they drive 
inflammation. Knowing that bacterial-derived antigens are a major source of antigens in 
the GI tract, we hypothesized that these antigens might promote the activation of T cells 
lacking Ndfip1 and thus drive GI inflammation in the GI tract.   
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Figure 2:  Ndfip1-cKO mice show increased inflammation and eosinophilia between 3 and 5 weeks of 
age. 
(A–D) Ndfip1-cKO and control mice were analyzed at 3 weeks and 5 weeks of age for signs of inflammation. 
Representative histology or flow plots from each group are shown. (A) Histological sections of esophagus 
were taken from Ndfip1-cKO and control mice at 3 weeks and 5 weeks of age, were stained with H & E and 
analyzed by microscopy using a 10× objective. (B–C) Representative flow cytometric analysis of cells 
isolated from the esophagus (B) and small bowel (C). Plots show CD45+, live gated cells. Eosinophils 
(Siglec F+ cells) and CD4+ T cells are shown. Percentages of populations in the gated regions are 
indicated. Representative flow cytometric analysis of splenic CD4+ T cells (D). Gate on each plot represents 
cells defined as activated based on expression of CD44 and loss of CD62L. Percentage of cells in each gate 
is indicated. 
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Antibiotic Treatment of WT Mice Reduces Intestinal Bacteria and Does Not 
Significantly Alter T cell Activation or GI Eosinophilia  
While oral administration of a broad-spectrum cocktail of antibiotics in drinking water has 
been shown to be extremely effective in reducing intestinal bacteria, the unpleasant 
taste can cause mice to avoid drinking and lead to insufficient hydration in treated mice 
(98). To ensure effective knockdown of bacteria without causing dehydration, we 
modified the antibiotic regimen in Hill et al. (98) by reducing the concentration of 
antibiotics and adding sucralose, a non-nutritive sweetener, to encourage drinking. 
Control cages received drinking water with sucralose only. As shown in Figure 3 A, after 
13 days this treatment regimen reduced the amount of bacterial 16S rDNA detected in 
total stool DNA by over 100-fold. In addition, although the mice receiving antibiotics 
showed an initial loss of weight compared to mice receiving only sucralose, they gained 
weight steadily over the course of treatment and did not display scruffy coat, lethargy, or 
other signs of dehydration (Figure 3 B and data not shown). 
Following treatment, we analyzed wild type mice for signs of immunological changes 
caused by antibiotic treatment. Flow cytometric analysis revealed no difference in the 
activation of splenic CD4+ or CD8+ T cells (Figure 3 C and data not shown). 
Additionally, sections of the esophagus and small bowel did not show histological 
changes following antibiotic treatment (Figure 3 D-E).  
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Figure 3: Antibiotic treatment of wild type mice decreases bacterial load and does not produce overt 
immunological changes. 
(A) The average fold change in 16 s rDNA copies was quantified by qPCR from stool of wildtype mice 
treated with antibiotics and sucralose (n=5) or sucralose alone (n=3). Data shown is the fold change in 16S 
copies after 13 days of treatment. Error bars represent the SD. (B) The weight of mice treated with 
sucralose only (black line) or sucralose and antibiotics (dotted line) is shown over the course of treatment. 
Dot represents the mean of the population and error bars are the SD from the mean. (C) Percentages of 
activated splenic CD4+ T cells (defined as shown in Figure 2D) in mice treated with sucralose only or 
sucralose and antibiotics is shown. Each dot represents a single mouse. (D–E) Histological sections of the 
esophagus (D) and small bowel (E) are shown for mice treated with sucralose only (−antibiotics) or 
sucralose and antibiotics (+antibiotics). A 10× objective was used for esophagus and a 40× objective was 
used to analyze small bowel. 
Antibiotic Treatment of Ndfip1-cKO mice from 3-5 Weeks of Age Does Not 
Reduce Inflammation 
We next treated age-matched pairs of Ndfip1-cKO and control mice with oral antibiotics 
as described above. Similar to the results seen in WT mice, antibiotic treatment was 
extremely effective in reducing bacterial DNA detected in stool and did not cause weight 
loss (Figure 4 A-B). Furthermore, no significant differences were seen in the total 
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amounts of bacteria, as determined by comparing the concentration of 16s rDNA 
between Ndfip1-cKO mice and controls, between the two genotypes either before or 
after antibiotic treatment (data not shown). Despite drastically reducing bacterial flora, 
antibiotic treatment of Ndfip1-cKO animals did not produce any discernible decrease in 
inflammation of the esophagus or small bowel. For example, we did not observe a 
decrease in the hypertrophy in the epithelial esophagus or the number of visible 
eosinophils infiltrating into the villi of the small bowel following treatment with antibiotics 
(Figure 4 C). Furthermore, flow cytometry revealed no significant change in the 
percentages of activated CD4+ T cells isolated from the spleen or mesenteric lymph 
nodes following antibiotic treatment (Figure 4 D and data not shown).  
Antibiotic Treatment of Ndfip1-cKO Mice from Birth to 5 Weeks of Age Does Not 
Reduce T cell activation or GI Tract Inflammation 
Because Ndfip1-cKO mice begin to show signs of T cell activation and eosinophilic 
infiltration into the GI tract as early as three weeks of age, we wondered whether 
administration of antibiotics beginning at 3 weeks was too late. We hypothesized that 
treatment from birth would be more effective in reducing pathology. To test this, we 
administered broad-spectrum antibiotics to pregnant females beginning 1 day prior to 
their expected delivery date as described above. Treatment continued until mice were 
analyzed at 5 weeks of age.  Antibiotic treatment of Ndfip1 cKO animals using this 
regimen resulted in similar levels of 16S rDNA in stool at 5 weeks of age as when 
treatment was administered from 3-5 weeks of age (data not shown). Importantly, mice 
treated with antibiotics gained weight steadily over the course of treatment (Figure 5 A).  
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Figure 4: Ndfip1 CD4-cKO mice treated with antibiotics for 2 weeks do not show decreased 
eosinophilia or reduced inflammation in the esophagus. 
(A) The average 16s rDNA copies/nanogram of total stool DNA was quantified by qPCR at day 0 and day 13 
of treatment with sucralose alone (n=5) or sucralose and antibiotics (n=4). Error bars illustrate SD. (B) 
Weights of mice treated with sucralose alone (solid line) or antibiotics and sucralose (dashed line) over the 
course of the 13 day treatment. (C) Representative H & E stained histological sections of the esophagus and 
small bowel of Ndfip1-cKO mice after 13 days of treatment with sucralose alone or antibiotics and sucralose 
are shown. (D) Percentages of activated CD4+ T cells in the spleens of mice treated with sucralose only 
(untreated) or with antibiotics and sucralose (treated) as determined by flow cytometric analysis. Each dot 
represents a single mouse. 
   
Similar to our observations of mice treated from 3-5 weeks of age, we did not observe 
any visible reduction in inflammation following antibiotic treatment from birth. The 
esophageal epithelium of Ndfip1 cKO mice treated from birth was inflamed compared 
with age-matched controls (Figure 5 B).  Flow cytometric analysis of cells isolated from 
the esophagus and small bowel revealed increased percentages of eosinophils in 
Ndfip1-cKO compared with controls (Figure 6 A-D). The representative plot in figure 5C 
23 
 
shows increased percentages of (Siglec F+) eosinophils among cells isolated from the 
esophagus (Figure 6 A) or small bowel (Figure 6 C) of an Ndfip1-cKO mouse. 
Furthermore, elevated percentages of eosinophils in these tissues were observed in all 
Ndfip1-cKO animals under investigation (Figure 6 B and D).   Additionally, all Ndfip1-
cKO mice examined demonstrated a substantial increase in the percentages of activated 
T cells in their spleens after this course of antibiotic treatment (Figure 6 E and F). The 
percentages observed were similar to those percentages in untreated 5 week old Ndfip1-
cKO mice. Thus, we do not see any decrease in the inflammatory phenotype of Ndfip1-
cKO mice treated with antibiotics from birth until five weeks of age. Therefore, starting 
the antibiotic treatment at birth and treating mice until 5 weeks of age did not improve T 
cell activation or inflammation in Ndfip1-cKO mice. 
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Figure 5: Ndfip1 CD4-cKO mice treated with antibiotics from birth do not show changes in 
eosinophilia or inflammation in the esophagus, or splenic T cell activation. 
(A) Weights of control mice (n=4) (closed circles) or Ndfip1-cKO mice (n=4) (open circles) between weeks 3 
to 5 of antibiotic treatment. (B) H & E stains of histological sections of esophagus taken from control and 
Ndfip1-cKO mice after antibiotic treatment from birth to 5 weeks. Images were taken using a 20× objective. 
Inset of panel outlined by the box is shown in the images on the right. 
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Figure 6: Antibiotic Treatment of Ndfip1 cKOs from Birth Does Not Reduce Inflammation. 
(A–D) Representative flow cytometry plots of cells isolated from the esophagus (A) and small bowel (C) of 
Ndfip1-cKO and control animals treated from birth to 5 weeks. Graphs of the percentages of eosinophils 
(Siglec F+) and CD4+ T cells in esophagus (B) or small bowel (D) from all mice in the experiment are 
shown. (E) Representative flow plots illustrating the percentage of activiated cells among splenic CD4+ 
gated T cells. (F) Percentages of activated T cells in the spleens of all mice treated with antibiotics from birth 
to 5 weeks are shown. 
 
Discussion 
In this study, we found that treatment of Ndfip1-cKO mice with oral antibiotics did not 
significantly reduce T cell activation or gastrointestinal eosinophilia and inflammation. No 
discernible decrease in T-cell activation or eosinophil infiltration was seen in Ndfip1-cKO 
mice regardless of whether they were treated with antibiotics for two weeks, from 3-5 
weeks of age, or treated from birth to 5 weeks of age. This was true despite the efficacy 
of antibiotic treatment in reducing the total GI bacterial load by more than 100 fold. 
These results suggest that gut microbiota do not play a significant role in the 
development of GI inflammation in Ndfip1-cKO mice.  
Microbiota are known to influence many aspects of immune function (98–100). In a study 
using oral gavage to administer a similar regimen of antibiotics to WT mice, Hill et al. 
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(98) demonstrated that a ten-fold reduction of 16S rDNA in stool. This decrease in GI 
microbiota correlated with reduced production of IL-17, a cytokine associated with 
specific types of bacteria (101–103), by intestinal CD4+ T cells. Our antibiotic treatment 
reduced the number of bacterial 16S rDNA copies detected in stool by over 100-fold 
after two weeks. Given the drastic reduction in total bacterial load after antibiotic 
treatment, we consider it unlikely that any remaining bacteria would provide sufficient 
antigenic stimulation of the immune system to induce inflammation in Ndfip1 cKO mice. 
While it remains possible that some bacteria are resistant to the antibiotic treatment and 
remain in the gut, the ~100 fold decrease in bacterial load did not correlate with any 
discernable decrease in the percentages of activated T cells in Ndfip1-cKO mice. This 
leads us to conclude that few, if any, Ndfip1-/- T cells are activated by bacterial antigens. 
Thus, the activation of T cells lacking Ndfip1 likely can be induced by other 
environmental antigens or self-antigens. This sensitivity to other antigen sources may be 
due, in part, to the relative decrease in iTregs observed in Ndfip1-defiicent mice (104). 
Indeed, CNS1-deficient mice, which lack iTregs and develop spontaneous Th2-polarized 
intestinal inflammation similar to that observed in Ndfip1KO mice, also do not show 
improvement when treated with antibiotics (105).  
Our study shows that gastrointestinal microbiota do not play a significant role in the 
development of GI inflammation in Ndfip1-cKO animals, but it is possible that other types 
of environmental antigens are responsible for inflammation in Ndfip1-deficient mice. In 
addition to bacterial-derived antigens, food antigens have also been implicated in the 
pathogenesis of IBD (99). Supporting this, food restriction diets have been shown to 
improve IBD symptoms in human patients and in animal models (100, 101, 106).  
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Food antigens are also associated with other eosinophilic GI disorders. Eosinophilic 
gastrointestinal disorders (EGID) are chronic diseases characterized by increased 
numbers of eosinophils in the digestive tract. These disorders, all of which are 
associated with food allergy, include eosinophilic esophagitis (EoE), eosinophilic gastritis 
(EG) and gastroenteritis (EGE), and eosinophilic colitis (EC). Because of its association 
with food allergy, diet has been used to treat patients with EoE (102, 103). The high 
degree of esophageal inflammation, revealed by eosinophilia and epithelial hypertrophy, 
in Ndfip1-cKO animals bears a strong resemblance to the pathology of EoE and EGE.  
Thus, Ndfip1-cKO mice may serve as a model for these disorders. This is of particular 
significance since patients with EoE commonly have other allergic diseases such as 
asthma and atopic dermatitis. Mice lacking Ndfip1 also develop atopic inflammation in 
the skin and lung. This might suggest that, like with patients with EoE, eosinophilia and 
GI inflammation in Ndfip1-/- mice is caused by aberrant immune responses to food 
antigens.  
Materials and Methods  
Mice  
Ndfip1-cKO mice have been described (94). All experiments described in this manuscript 
compare Ndfip1-cKO mice to littermate controls. These controls include mice with one or 
two Ndfip1 floxed alleles but not expressing Cre, or mice expressing Cre that do not 
have either Ndfip1 allele floxed. No differences were observed when comparing these 
two types of controls. All mice were bred in the Children’s Hospital of Philadelphia 
animal facility. All experimentation was approved and followed guidelines established by 
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the institutional animal care and use committee of the Children’s Hospital of 
Philadelphia.  
Genotyping  
Ndfip1-cKO mice were genotyped using purified genomic DNA from tail samples and the 
following PCR primers: Ndfip1 floxed forward 5’-TGAGGAAACAGACACACAATG-3’, 
Ndfip1 floxed reverse 5’- TGGAATGAACCTGAGGTCTCC-3’. Samples were amplified 
using conventional PCR techniques and run by electrophoresis on a 1% agarose gel. 
Wild type DNA forms an approximately 1kb band and Ndfip1-/- DNA yields an 
approximately 340 bp band.  
Antibiotics  
Animals were provided with autoclaved drinking water supplemented with sucralose (1.5 
mg/ml) or autoclaved drinking water supplemented with sucralose (1.5 mg/ml), ampicillin 
(0.5 mg/ml), gentamicin (0.5 mg/ml), metronidazole (0.5 mg/ml), neomycin (0.5 mg/ml) 
and vancomycin (0.5 mg/ml). For mice treated upon weaning, animals were 26 days old 
at the start of treatment and were sacrificed 14 days later. For mice treated since birth, 
pregnant females were treated starting approximately 1 day before giving birth until their 
litters were weaned, at which point weaned pups were treated for a further 14 days and 
sacrificed.  
Lymphocyte isolation from tissues 
At necropsy, mesenteric lymph nodes (mLN), spleen, esophagus and small bowel were 
harvested. Single-cell suspensions of spleen and mLN were prepared by mashing tissue 
through a 70µm filter.  LNs were then washed and resuspended in phosphate-buffered 
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saline (PBS). Splenic red blood cells were lysed with ACK buffer (.15M Nh4Cl, 10mM 
KHCO3, .1mM EDTA) and samples were then washed and resuspended in PBS.  
For preparation of lymphocytes from the small bowel, a 3-4 inch section of small bowel 
was removed. Peyer’s patches were excised and the luminal contents were removed.  
Small bowel and esophagus samples were minced and then digested in medium 
containing collagenase type 1, collagenase type 1a, and DNAse for approximately one 
hour at room temperature. Samples were then strained through a 100µm filter, washed 
with Dulbecco’s Modified Eagle Media (DMEM), and filtered again through a 40µm filter. 
Flow Cytometry  
Single-cell suspensions of lymphocytes isolated from tissues were stained for surface 
expression using fluorochrome conjugated anti-CD3, anti-CD8α, anti-CD8β, anti-CD4, 
anti-F4/80, anti-CD62L, anti-CD44, and anti-Siglec-F (anti-Siglec-F was purchased from 
BD Biosciences; all other antibodies were purchased from Biolegend). Cells were 
stained for 30 minutes on ice and washed twice with PBS containing fetal calf serum and 
sodium azide (FACS buffer). Flow cytometry was performed on an LSRFortessa flow 
cytometer (BD Biosciences) and results were analyzed using Flow-Jo software (Treestar 
USA).  
Histological Analysis 
At necropsy, small bowel and esophagus sections were removed, fixed in 10% formalin 
for 48 hours, and embedded in paraffin. Sections were stained with eosin and 
hematoxyin. Stained sections were analyzed using a Leica microscope (Bannockburn, 
IL) with a bright field objective. 
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DNA Extraction  
Stool samples were collected on day 0 of the experiment prior to sucralose or antibiotic 
administration and on day 13 (for mice treated upon weaning) or day 34 (for mice treated 
since birth). Samples were stored at -80 C and later defrosted and lysed by bead beating 
using the Mini BeadBeater-16 (Biospec). The samples were then prepared using the 
QiaAmp DNA Stool Mini Kit (Qiagen) according to the manufacturer’s instructions. Final 
DNA concentrations were measured using a Thermo Nanodrop 2000.  
Bacterial quantitation by 16S qPCR  
16S quantitation was performed using real-time PCR of 20 uL triplicate reactions 
containing 10 ng stool DNA, TaqMan Environmental Master Mix 2.0 (Applied 
Biosystems), and primers/probe specific for bacterial 16S rDNA as described by Hill, et 
al. (98). Standard curves with a range of 101 to 2 x 107 copies of E. coli 16S rDNA were 
prepared using linearized plasmid containing a single copy of the 16S gene.  
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CHAPTER 3: PERIPHERAL IL-4 DRIVES EXPANSION OF VIRTUAL MEMORY 
CD8+ T CELLS 
Introduction 
Memory CD8+ T cells arise from naïve CD8+ T cells following antigen stimulation and 
effector differentiation. While several different subsets of memory cells have been 
described, they generally share certain phenotypic and functional similarities, such as 
high CD44 expression in the absence of recent activation (107, 108). In human cells, 
CD45 isoforms can also be used to identify memory T cells, which primarily express 
CD45RO (109–111). In addition to the conventional pathway of antigen-induced memory 
cell development, several observations suggest the existence of an alternative pathway 
to a memory-like phenotype. Naive mice on a variety of genetic backgrounds contain a 
percentage of CD44hi T cells (112, 113). This population is observed even in mice bred 
under germ-free conditions (114, 115) and increases with age (116–118). Memory-
phenotype T cells can even be detected in human fetal spleen and umbilical cord blood 
(119, 120). Below, we discuss evidence that CD8+ T cells can acquire a memory-like 
phenotype driven primarily by exposure to cytokines and weak TCR signals rather than 
overt antigen stimulation. Collectively, these are termed “alternative memory” cells (121), 
and they arise in a variety of contexts.    
Homeostatic proliferation 
Normal, healthy hosts maintain naïve and memory CD8+ T cell populations through 
mechanisms that ensure both survival of cells and basal levels of self-replication through 
homeostatic proliferation (HP). Naïve CD8+ T cells, which express high levels of IL-7Rα 
(CD127) but low levels of IL-2/IL-15Rβ (CD122), are long-lived but rarely divide; in 
contrast, most central memory CD8+ T cells express high levels of both CD127 and 
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CD122, are also long-lived, and proliferate slowly over time (107, 122–124). Although 
naïve CD8+ T cells require tonic stimulation of the TCR by self-peptide ligands for 
survival, the survival of memory CD8+ T cells is largely MHC-independent (125, 126). 
Memory CD8+ T cells require IL-15 to undergo basal homeostatic division, and rely on 
both IL-7 and IL-15 for survival (127–131). The exception to the previous statements is a 
small population of memory CD8+ T cells which are CD44hi CD122lo; these cells don’t 
require IL-15 for survival but do depend on MHC class I (128, 132). The apparent 
requirement for either TCR stimulation or IL-15 signaling to sustain memory CD8+ T cells 
is perhaps not surprising, as IL-15 and anti-CD3 induces similar proliferation, cytokine 
production, and changes in gene expression when used to stimulate memory cells in 
vitro (133). Survival of naïve CD8+ T cells is mainly dependent on IL-7, although IL-15 
also contributes (130, 134, 135). However, large amounts of either cytokine may be able 
to substitute for the other. For example, artificially increasing IL-7 levels by giving WT 
mice IL-7/mAb complexes induces proliferation of naïve and memory T cells (136). 
In contrast to basal homeostatic proliferation, acute HP is induced when naïve T cells 
are transferred to recipients that lack lymphocytes, typically mice deficient in one of the 
Rag proteins or mice that have been irradiated. Naïve CD8+ T cells in such a 
lymphopenic environment proliferate and acquire a memory phenotype even in the 
absence of cognate antigen (137–140). This homeostatic proliferation does not require 
IL-2 or costimulation through CD28/B7, 4-1BB/4-1BBL, or CD40L/CD40 (138, 141). 
Rather, it is driven by the relative increase of IL-7 in lymphopenic hosts in concert with 
TCR signaling from low-affinity self-ligands and ligands derived from commensal 
bacteria (129, 135, 142, 143). Recently, TGF-β was found to be necessary for enforcing 
the IL-7 and IL-15 dependence of HP, as CD8+ T cells expressing a dominant-negative 
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TGF-β transgene proliferated and developed a memory phenotype in the absence of IL-
7 and IL-15 (144). 
HP-derived memory cells are functionally very similar to antigen-induced memory cells. 
HP memory CD8+ T cells expressing the transgenic 2C TCR were able to mediate target 
cell killing in vitro as well as memory 2C cells generated following peptide immunization, 
and performed nearly as well in suppressing the growth of tumor cells in vivo (138). 
However, homeostatic proliferation does not result in a distinct effector population and 
takes longer to generate cytolytic cells than peptide immunization (137, 138). OTI HP 
memory cells produce IFNγ and TNFα upon peptide stimulation ex vivo as well as 
conventional memory cells (145). In addition, they are able to mediate protection against 
infection by ovalbumin-expressing Listeria, but only if generated in the presence of CD4+ 
T cells (145, 146). This is extremely similar to the requirement for CD4+ “help” in the 
conventional generation of protective CD8+ memory T cells (147, 148). In both cases, 
CD4+ T cells act by stimulating CD40 on dendritic cells (145, 146, 149). Stimulation 
through CD40-CD40L interactions enables dendritic cells to prime IL-2 production in 
CD8+ T cells that enhances T-cell survival upon subsequent antigen encounter (150–
152). However, differences in HP memory responses versus conventional memory 
responses are observed when both types of cells are co-transferred into hosts which are 
then immunized. In this situation, HP memory cells proliferated less and generated fewer 
“secondary” memory cells than did conventional memory cells, possibly due altered 
localization within the spleen (153).  
What has been described thus far may be considered “slow” acute HP and, as 
previously mentioned, is mediated largely by IL-7 and self-peptide ligands. However, 
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“fast” acute HP, in which naïve T cells proliferate and acquire effector functions with 
kinetics similar to antigen-stimulated cells, has also been observed in certain situations. 
Slow HP occurs when polyclonal or monoclonal transgenic naïve T cells are transferred 
to irradiated WT recipients, or when monoclonal transgenic naïve cells are transferred to 
chronically lymphopenic recipients (e.g. Rag1KO or nude mice). When polyclonal naïve 
T cells are transferred to chronically lymphopenic recipients, however, a subset of the 
cells proliferates very rapidly and quickly outnumbers the slowly dividing cells (154). 
Unlike cells undergoing typical slow acute HP, these rapidly dividing cells express the 
activation marker CD25 and produce IFNγ at 8 days post transfer (140, 142, 154). The 
factors that drive fast HP are different from those that drive slow HP, since fast HP still 
occurred in the absence of IL-7 (154). Additionally, when germ-free Rag1KO mice were 
used as recipients, only slow HP occurred, suggesting that the microbiota of chronically 
lymphopenic mice is a major source of antigen for fast HP (154). 
Interestingly, fast HP can also be induced in naïve monoclonal transgenic T cells, 
providing they are transferred to CD132-defiicent mice. CD132KO mice are lymphopenic 
but also have elevated levels of IL-2 and IL-15. When naïve transgenic or polyclonal 
cells are transferred to CD132KO mice, they proliferate and become cytokine producers 
even more rapidly than described above for polyclonal T cells transferred to Rag1KO 
mice (155). Proliferation was reduced in the absence of either IL-2 or IL-15 but not IL-7, 
and was also reduced in B2m-deficient hosts, which cannot display MHC class I (155). 
This suggests that fast HP, although reliant on different cytokines than slow HP, still 
depends partly on TCR stimulation.  
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Fast HP also occurs in lympho-sufficient mice. When naïve cells are transferred to 
CD122-deficient mice, which have increased levels of IL-2 and probably IL-15 but 
normal T-cell numbers, or when mice are injected with exogenous IL-2/mAb complexes, 
they proliferate and briefly express CD25 and CD69 with kinetics similar to polyclonal 
cells transferred to Rag1KO mice (156, 157). As with CD132KO mice, polyclonal as well 
as transgenic monoclonal naïve T cells were able to proliferate in CD122KO hosts, and 
this was reduced in the absence of IL-2, IL-15, and MHC class I (157). IL-2-induced HP 
memory OTI cells protect against challenge by ovalbumin-expressing Listeria, despite 
the fact that they are somewhat less effective than conventional antigen-specific memory 
cells at producing cytokines upon in vitro stimulation with peptide or PMA and ionomycin 
(156). IL-2 treatment also leads to expansion of the endogenous memory-phenotype 
population, including antigen-specific cells from unimmunized mice, which are often 
called “virtual memory” (VM) cells (158). 
Virtual memory CD8+ T cells 
Cells that closely resemble HP memory cells also arise in unmanipulated, lympho-
sufficient hosts. These cells have been termed “virtual memory” (VM) cells (159–162). 
VM cells are a subset of the endogenous CD8+ T cell population and display a distinct 
memory phenotype identical to that of HP memory cells: CD44hi CD122hi CD49dlo. 
CD49d (α4 integrin) levels increase upon antigen stimulation and are higher on antigen-
induced memory cells than HP memory cells or VM cells (142, 153, 159, 162, 163). 
CD49d has thus been suggested as a potential marker to distinguish VM cells from true 
antigen-experienced memory cells (162).  Like HP memory cells, VM cells develop even 
in the absence of exposure to cognate antigen. This has been confirmed by using 
tetramers loaded with various specific peptides to isolate antigen-specific CD8+ T cells 
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from unimmunized B6 mice. Memory-phenotype CD8+ T cells specific to peptides 
derived from ovalbumin, vaccinia virus, herpes simplex virus 1, influenza virus, and 
mouse cytomegalovirus have all been observed in naïve mice (159, 161, 164). These 
VM cells are present even in germ-free mice (159). 
VM cells appear in the periphery rapidly following the postnatal period, reaching their 
peak frequency at approximately 3 weeks of age (161). Because neonatal mice support 
lymphopenia-induced proliferation (165, 166), and because of their many phenotypic 
similarities to HP memory cells, VM cells are often assumed to be naturally-occurring HP 
memory cells (159, 161, 162). Notably, cytokines play an important role in the 
development or maintenance or VM cells. VM cells are nearly absent in mice deficient in 
IL-15Rα, suggesting a strong link between IL-15 signaling and VM cells. Additionally, a 
smaller but statistically significant decrease in the percent of VM cells among total 
splenic CD8+ T cells is seen in IL-4KO and IL-4RαKO mice compared to WT B6 mice, 
from approximately 15% to approximately 10% (161, 162) and (Figure 14). This may 
suggest a relatively minor role for IL-4 in the generation or maintenance of VM cells, but 
could also reflect the fact that naïve WT B6 mice produce little IL-4 and thus IL-4 may 
only affect a subset of CD8+ T cells in these mice. The role of abundant IL-4 on CD8+ T 
cells will be the subject of much of this chapter. 
Regardless of their origins, once established VM cells undergo basal homeostatic 
proliferation at a rate roughly comparable to the bulk CD44hi CD8+ T cell pool, and 
individual clones within the VM population remain stable even when hosts are infected 
with unrelated pathogens (i.e. induction of antigen-specific memory T cells does not 
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diminish the VM pool) (161). Further, the VM cell population expands in aging mice, 
though this is accompanied by reduced TCR diversity (160).  
Functionally, VM cells are broadly similar to antigen-induced memory cells, with some 
interesting differences. Although both conventional antigen-induced memory CD8+ T 
cells and VM cells express both the transcription factors T-bet and Eomes, VM cells 
have a higher Eomes:T-bet ratio than conventional memory cells (167). When 
transferred to recipients that are subsequently infected with Listeria, antigen-specific VM 
cells expand with the same magnitude and kinetics as conventional memory cells, 
though they preferentially acquire a KLRG1- CD127hi phenotype (167). These 
experiments concluded that VM and conventional memory cells provide comparable 
protection against Listeria infection, as VM cells were at least as effective at controlling 
bacterial loads as were conventional memory cells (167). Surprisingly, VM cells are 
severely impaired in IFNγ production upon stimulation with peptide both in vivo and in 
vitro compared to conventional antigen-induced memory cells, although they exhibit 
largely similar IFNγ production to conventional memory cells when stimulated with IL-12 
and IL-18 (159, 167, 168).  
In this respect, VM cells most resemble HP memory cells generated by injection of IL-
2/IL-2 mAb complexes. As described above, these cells are also less likely to produce 
IFNγ than conventional memory cells upon stimulation with peptide or PMA and 
ionomycin, but are nearly as likely to produce IFNγ when stimulated with IL-12 and IL-
18, and are protective against Listeria challenge (156, 158, 168). This is in contrast to 
HP memory cells generated by naïve-cell transfer into irradiated WT hosts or into 
CD132KO hosts, both of which display normal IFNγ production upon stimulation with 
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peptide, albeit with much different kinetics (145, 155). The source of functional 
heterogeneity among HP memory cells generated by different means, and between VM 
cells and HP memory cells, is worthy of further study. 
VM-like cells are also observed in mice deficient for IFN regulatory factor 4 (IRF4KO 
mice) (169). In IRF4KO mice, peripheral but not thymic CD8+ T cells develop a memory 
phenotype due to both an intrinsic propensity to upregulate Eomes expression and 
extrinsic factors, including reduced numbers of Tregs. Accordingly, a small but 
statistically significant percentage of WT OTI cells transferred to IRF4KO mice acquire a 
memory phenotype, while a larger percentage of IRF4KO OTI cells transferred to WT 
donors do so. IL-4 did not appear to affect the percentage of Eomes+ cells in vivo or in 
vitro, though it increased per cell Eomes expression in IRF4KO cells in vitro and possibly 
in vivo. Because CD49d expression was not examined on these cells, and because they 
have an intrinsic defect in Eomes regulation, it is not clear whether these cells should be 
classified as VM cells. 
Innate CD8+ T cells 
Memory phenotype CD8+ T cells have also been characterized in a variety of genetic 
models that result in increased percentages of thymic PLZF+ IL-4-producing cells (121). 
In these models, IL-4 acts in trans to induce a memory phenotype in bystander CD8 SP 
thymocytes (Table 1). These bystander CD8+ T cells are typically called “innate” CD8+ T 
cells. 
It is worth pausing here to discuss nomenclature. The term “innate” or “innate-like” has 
been used for some time to describe T cells that acquire an activated/memory 
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phenotype, including rapid cytokine production upon stimulation, in the thymus as part of 
their maturation process (170). Major innate-like populations include Cd1d-restricted 
TCRαβ-expressing NKT cells and TCRγδ-expressing cells (some of which also express 
NK receptors and are considered a type of NKT cell). These cells do not express CD8 
and may or may not express CD4. PLZF is essential for the memory phenotype of these 
cells (171, 172). Moreover, transgenic expression of PLZF in all T cells leads to a 
dramatic increase in memory-phenotype, polyclonal, non-NKT CD4+ and CD8+ T cells, 
with increased IL-4 production from CD4+ T cells and increased IFNγ production from 
CD8+ T cells (173–175). PLZF overexpression was also able to induce a memory 
phenotype in CD4+ T cells with a transgenic TCR specific for either HY antigen or 
ovalbumin, indicating that this function of PLZF is independent of exposure to cognate 
antigen (175). Additionally, several populations of innate-like CD8+ T cells selected on 
nonclassical MHC Class Ib molecules, such as H2-M3 and MR1, have also been 
observed (176–179). When increased numbers of CD8 SP thymocytes with a similar 
phenotype to innate T cells were observed in ItkKO mice (discussed further below), 
these cells were also called “innate CD8+ T cells” (170, 180). However, it is now clear 
that these memory-phenotype CD8+ T cells differ from the innate T cells previously 
described in important ways. First, this new cell type resembles conventional T cells in 
that it can display a diverse range of TCRs (181, 182). Second, the memory phenotype 
is nearly always dependent on IL-4 produced by PLZF+ CD4+ T cells, rather than due to 
a cell-intrinsic effect of the genetic mutation in question. Nevertheless, the name has 
stuck. Although we prefer the general term “non-conventional” to “innate”, we will 
continue to refer to such cells as “innate CD8+ T cells”  in this manuscript when 
distinguishing them from VM cells.  
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Finally, all of the types of T cells just discussed should not be confused with “innate 
lymphoid cells” (ILCs). ILC is a term which describes innate cells, such as NK cells, that 
have lymphoid morphology but do not express TCRs or myeloid or dendritic cell lineage 
markers (183, 184). 
One of the earliest, and perhaps best-studied, examples of innate CD8+ T cells occurs in 
mice deficient for the Tec kinase Itk (180, 185–188). These mice have an increased 
population of thymic PLZF+ IL-4+ γδ NKT cells, and the IL-4 these cells produce is 
sufficient to drive CD8+ SP thymocytes to acquire a memory-like phenotype including 
high levels of CD44, CD122, and Eomes, as well elevated CD124 (IL-4Rα) expression. 
This phenotype is even more pronounced in mice deficient for both Itk and another Tec 
kinase, Rlk. A similar phenotype arises in SLP-76:Y145F mice, which have a mutation in 
Src homology 2 domain-containing leukocyte protein of 76 kDa (SLP-76) at residue 145 
(189–191). Additionally, expanded populations of γδ and/or αβ PLZF+ IL-4+ NKT cells 
lead to increased innate CD8+ T-cell populations in mice deficient for Id3 (190, 192–
194), Klf2 (188, 195), Ly9 (196) and mice which express stabilized transgenic β-catenin 
(197, 198). A cell-extrinsic increase in innate CD8+ T-cells is also observed in mice 
lacking thymic expression of CBP, although the dependence of this phenotype on IL-4 or 
PLZF has not been formally studied (188, 199).  
Another type of PLZF+ IL-4+ cell has also been observed to drive an increase in innate 
CD8+ T cells: CD4+ thymocytes selected through homotypic interactions with other 
thymocytes in mice expressing transgenic MHC Class II (181, 200–202). This process 
may occur in humans, as human thymocytes express MHC II and populations of both 
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PLZF+ CD4+ T cells and memory-phenotype CD8+ T cells have been found in human 
fetal spleen and cord blood (181, 202).  
Innate CD8+ T cells arise naturally in BALB/c mice, which have a much larger proportion 
of PLZF+ IL-4+ NKT cells in the thymus than C57BL/6 mice (188, 203). A few innate 
CD8+ T cells are present in C57BL/6 thymi, but the population is very small. However, a 
study by Rafei et al. found that ~10% of CD8 SP thymocytes in C57BL/6 were “innate”. 
This discrepancy may be explained by the more permissive gating strategy in the Rafei 
et al. study, which used only CD44 and Rag2p-GFP to define the innate population. In 
contrast, other studies have gated on CD44hi CD122hi cells, which appear to be a 
smaller population (188).  
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Table 1: Genetic models which give rise to innate CD8+ T cells1 
1This is an updated version of Table 1 from Lee et al. (121). 2n.d. = not done. 
Mouse 
Model 
Eomes in 
CD8 SP 
thymocytes 
Cell‐
extrinsic 
Requires 
IL‐4 
Role of PLZF/NKT 
cells 
Antigen‐ 
indepen. 
Elevated 
IFNγ  Ref. 
WT Balb/c  elevated  Y  Y 
‐Increased PLZF+ 
thymocytes 
compared to Bl/6  
‐Dependent on CD1d 
n.d.  Yes, after PMA/iono 
(188, 
203) 
Itk‐/‐  elevated  Y  Y 
‐Increased γδ NKT 
 ‐Dependent on PLZF 
and SAP 
n.d. 
Yes, after 
PMA/iono 
& IL‐12/IL‐
18 
(180, 
185–
188) 
Klf2fl/fl 
CD4Cre  elevated  Y  Y 
‐Increased γδ and αβ 
NKT  
‐Dependent on PLZF 
Y 
Yes, after 
PMA/iono 
& IL‐12/IL‐
18 
(188, 
195) 
Cbpfl/fl LckCre  elevated  Y  n.d.  n.d.  n.d.  Yes, after PMA/iono 
(188, 
199) 
SLP76:Y145F  elevated  Y  Y  ‐Increased γδ NKT ‐Dependent on PLZF  n.d. 
Yes, after 
PMA/iono 
(189–
191) 
Id3‐/‐  elevated  Y  Y 
‐Increased γδ and αβ 
NKT 
‐Dependent on PLZF 
and SAP 
n.d.  Yes, after PMA/iono 
(190, 
193, 
194) 
CIITAtg  elevated  Y  Y 
‐Increased PLZF 
expression in 
polyclonal CD4+ T 
cells  
‐Dependent on PLZF 
and SAP  
n.d.  Yes, after PMA/iono 
(181, 
200–
202) 
B‐CATtg  elevated  Y  Y  ‐Increased PLZF+ αβ NKT  n.d. 
Yes, after 
PMA/iono 
(197, 
198) 
Ly9‐/‐  elevated  n.d.2  Y  ‐Increased PLZF+ αβ NKT  n.d. 
Yes, after 
PMA/iono  (196) 
Nfκb1‐/‐  elevated  Y/N  n.d. 
‐No elevated PLZF+ 
or NKT population; 
no elevated IL‐4 
Y  Yes, after PMA/iono  (204) 
 
 
The different natures of the systems used to study innate CD8+ T cells and VM cells 
means that much of the published data on these populations are not directly 
comparable. For example, innate CD8+ T cells uniformly produce elevated IFNγ upon 
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stimulation with PMA and ionomycin, as well as in response to IL-12 and IL-18 
stimulation (187, 188) and peptide stimulation (182). However, it is unknown whether 
they respond less efficiently to peptide stimulation than conventional memory cells, as 
sometimes observed in VM and HP memory cells. As there is no reason to expect VM 
cells in WT mice to express the elevated levels of CD124 observed in IL-4-driven innate 
cells, this receptor has not been examined on VM cells. Further, CD49d expression is 
relatively uncharacterized in innate CD8+ T cells compared to VM cells. Sosinowski et al. 
(162) found that CD49d expression was not lower on Id3KO CD44hi CD122hi CD8+ T 
cells than WT cells, and proposed that CD49d can therefore distinguish between VM/HP 
memory cells and innate CD8+ T cells. However, Weinreich et al. observed low CD49d 
expression on innate CD8+ T cells induced by Klf2 deficiency (188).  
Because innate CD8+ T cells arise in the thymi of unimmunized mice and exhibit a 
diverse TCR repertoire (181, 182), it is generally assumed that they do not require 
stimulation by cognate antigen. However, this is rarely tested directly. Before it was 
appreciated that  innate CD8+ T cells develop based on cell-extrinsic factors, Atherly et 
al. (185) generated Itk-deficient OTI mice and observed a loss of the innate phenotype 
that was likely due to the absence of IL-4+ NKT cells. Rafei et al. (182) observed that 
CD44hi CD8 SP thymocytes were still present in OTI mice; however, as these mice were 
Rag1+/-, this population could have expressed endogenously rearranged TCRs not 
specific to ovalbumin. Huang et al. found that OTI bone marrow transferred into mice 
lacking MHC I developed into memory-phenotype cells, but this system forces CD8+ T 
cells to be selected on hematopoietic cells, a process which may itself impose a memory 
phenotype and which may not reflect the development of the normal innate population 
(182, 194, 205). The best experiment involved generating a mixed chimera from WT OTI 
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bone marrow and Klf2-deficient bone marrow (188). In this study, WT OTI cells in a 
predominantly Klf2-deficient environment acquired the innate phenotype, suggesting that 
generation of innate CD8+ T cells is antigen-independent. Overall, the relationship 
between VM cells and innate CD8+ T cells remains unclear (see Figure 7 for a summary 
of the alternative memory cells discussed here). 
Overview of this study 
Nedd4-family interacting protein 1 (Ndfip1) restricts IL-4 production in CD4+ T cells by 
facilitating degradation of the transcription factor JunB (89, 104). Ndfip1-deficient CD4+ T 
cells have increased JunB levels and consequently overproduce IL-4. This excess IL-4 
impairs Th17 and iTreg differentiation (104, 206). Whether loss of Ndfip1 and/or 
exposure to IL-4 affect CD8+ T cell development or function is not known. In this study, 
we show that IL-4 in the periphery of Ndfip1-/- mice is sufficient to induce an expanded 
population of memory phenotype CD8+ T cells. The cells are phenotypically identical to 
VM cells, despite arising in response to IL-4. These data suggest that the distinction 
between innate and VM CD8+ T cells is a result of particular experimental conditions that 
alter the relative amounts and locations of common gamma chain cytokines. Further, it 
raises the possibility that VM cells may be clinically relevant in diseases which are 
characterized by local increases in IL-4, such as asthma. 
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Figure 7: Diversity of alternative memory CD8+ T cells 
Alternative memory CD8+ T cells can arise in response to increased thymic IL-4 (left) produced by PLZF+ 
innate T cells (such as NKT cells), and in these models are called “innate CD8+ T cells.” They can also arise 
in the periphery due to homeostatic proliferation induced in experimental models (far right). Endogenous 
alternative memory CD8+ T cells, called “virtual memory” cells (near right), also arise in the periphery and 
are dependent on IL-15; however, the mechanisms underlying their development have not been fully 
elucidated. 
 
Results 
Innate-like CD8+ T cells develop in Ndfip1-deficient mice 
While Ndfip1 has a well-characterized role in activating ubiquitin complexes that prevent 
IL-4 production in CD4+ T cells, its function, if any, in CD8+ T cells is unknown. We 
therefore examined the phenotype of Ndfip1-/- CD8+ T cells ex vivo by staining 
splenocytes from WT or Ndfip1-/- mice for markers of activation and then analyzed 
expression by flow cytometry. We found that Ndfip1-/- mice have an increased 
percentage of memory-phenotype CD8+ T cells (Figure 8). Ndfip1-/- CD8+ T cells are 
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significantly more likely than WT CD8+ T cells to express high levels of CD44, CD122 
(IL-2Rβ), and the transcription factor Eomesodermin (Eomes) (Figure 8 A-B). Notably, 
Ndfip1-/- CD8+ T cells express less CD49d than WT CD8+ T cells (Figure 8 A-B), a 
feature characteristic of VM cells.  
Interestingly, Ndfip1-/- CD8+ T cells also express increased levels of CD124 (IL-4Rα) 
(Figure 8 A-B). CD124 is upregulated on T cells in response to IL-4 exposure (207) and 
high CD124 levels have been observed on innate-like CD8+ T cells that develop in an IL-
4-rich environment (188). This suggested that exposure to cytokine may drive Ndfip1-/- 
CD8+ T cells to acquire a memory-like phenotype. To test this, we generated chimeras 
by injecting WT (CD45.1+) or Ndfip1-/- (CD45.2+) fetal liver cells alone (“straight 
chimeras”) or mixed in equal measure (“mixed chimeras”) into sub-lethally irradiated 
Rag1-/- recipients. After reconstitution, we analyzed splenocytes from the chimeras by 
flow cytometry. As expected, CD8+ T cells from the straight Ndfip1-/- chimeras expressed 
higher levels of both CD44 and CD122 than CD8+ T cells from the straight WT chimeras 
(Figure 8 C-D). However, there was no significant difference between WT and Ndfip1-/- 
cells that developed in the mixed chimeras, and this was largely due to increased 
expression of CD44 and CD122 on WT cells that developed in the presence of Ndfip1-/- 
cells (Figure 8 C-D). Thus, the memory-like phenotype of Ndfip1-/- CD8+ T cells is cell-
extrinsic. In contrast, upon stimulation with anti-CD3, Ndfip1-/- CD4+ cells but not WT 
CD4+ cells produced IL-4 even in the mixed chimeras, suggesting that IL-4 production 
from Ndfip1-/- cells drives acquisition of a memory phenotype in bystander CD8+ T cells 
(Figure 8 E-F). CD8+ T cells, on the other hand, did not produce any IL-4 (data not 
shown).  
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Loss of Ndfip1 could potentially affect many cell types. To confirm that the memory 
phenotype of Ndfip1-/- CD8+ T cells does not require loss of Ndfip1 outside the T-cell 
compartment, we crossed Ndfip1fl/fl mice to mice expressing the Cre recombinase under 
the control of the CD4 promoter (CD4-cre+). The resulting mice (cKOs) lack Ndfip1 only 
in T cells. CD8+ T cells from these cKOs have a memory-like phenotype similar to that of 
CD8+ T cells from Ndfip1-/- mice (Figure 9 A-B; Figure 8 A-B). As expected, the CD4+ T 
cells from cKO mice are more likely than control cells to produce IL-4 in response to 
stimulation (Figure 9 C). These data indicate that loss of Ndfip1 in T cells only is 
sufficient to induce increased frequency of memory-like CD8+ T cells.  
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Figure 8: Cell-extrinsic memory phenotype of Ndfip1-/- CD8+ T cells. 
(A) Representative histograms of CD44, CD122, CD124, Eomes, and CD49d expression on splenic WT and 
Ndfip1KO CD8+ T cells. (B) CD44, CD122, CD124, Eomes, and CD49d expression on splenic WT and 
Ndfip1KO CD8+ T cells based on flow cytometric analysis. (C-F) WT (CD45.1+) or Ndfip1KO (CD45.2+) fetal 
liver was transferred singly or as a 50:50 mix into irradiated Rag1-/- recipients. Six week later, splenic CD8+ T 
cells were isolated and analyzed by flow cytometry. (C) Representative histograms of CD44 and CD122 
expression on CD8+ T cells from straight WT or Ndfip1KO chimeras (top) or from within one mixed chimera 
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(bottom). (D) CD44 and CD122 expression in straight and mixed chimeras based on flow cytometric 
analysis. (E-F) Spleen cells were stimulated with anti-CD3 for 4hrs. (E) Representative histograms of IL-4 
expression on CD4+ T cells from straight WT or Ndfip1KO chimeras (left) or from within one mixed chimera 
(right) after stimulation with anti-CD3 for 4 hrs. (F) IL-4+ cells as a percentage of total CD4+ T cells in straight 
and mixed chimeras after stimulation with anti-CD3 for 4 hrs.  p values determined by unpaired Student’s t-
test, except for comparisons within individual mixed chimeras in (D) and (F), which used paired Student’s t-
test. Data are representative of three-five (A-B) or two (C-F) independent experiments. NS, not significant 
 
The memory phenotype of Ndfip1KO CD8+ T cells is largely IL-4-dependent 
The previous experiments suggested that increased IL-4 in Ndfip1-/- mice causes CD8+ T 
cells to develop a memory-like phenotype. To test whether the CD8+ T-cell phenotype is 
really dependent on IL-4, we compared splenocytes from Ndfip1-/-IL4-/- mice and control 
Ndfip1+/+IL4-/- mice. Loss of IL-4 almost completely ablated the increase in memory-
phenotype cells observed in Ndfip1-/- mice (Figure 10). Expression of CD122, CD49d, 
and CD124 was not statistically different in Ndfip1-/-IL4-/- CD8+ T cells compared to IL4-/- 
controls (Figure 10 A-B). Further, the percentage of cells expressing high levels of CD44 
or Eomes was drastically reduced in Ndfip1-/-IL4-/- CD8+ T cells compared to Ndfip1-/- 
cells from IL-4-sufficient mice, although a small but statistically significant increase 
compared to IL4-/- controls remained (Figure 10 A-B; Figure 8 A-B). Therefore, the 
overwhelming majority of memory-phenotype CD8+ T cells in Ndfip1-/- mice require IL-4 
for their development or maintenance.  
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Figure 9: Loss of Ndfip1 in T cells is sufficient for increase in memory-phenotype CD8+ T cells. 
(A) Representative histograms of CD44, CD122, CD124, Eomes, and CD49d expression on splenic control 
(Ndfip1fl/fl CD4-Cre-) and cKO (Ndfip1fl/fl CD4-Cre+) CD8+ T cells. (B) CD44, CD122, CD124, Eomes, and 
CD49d expression on splenic control and cKO CD8+ T cells based on flow cytometric analysis. (C) IL-4+ 
cells as a percentage of total CD4+ T cells after stimulation with PMA and ionomycin for 4 hrs.  p values, 
unpaired Student’s t-test. Data are representative of two independent experiments. 
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Figure 10: IL-4 deficiency ablates the memory phenotype of Ndfip1-/- CD8+ T cells. 
(A) Representative histograms of CD44, CD122, CD124, Eomes, and CD49d expression on splenic IL4KO 
and IL4KO Ndfip1KO (DKO) CD8+ T cells. (B) CD44, CD122, CD124, Eomes, and CD49d expression on 
splenic IL4KO and DKO CD8+ T cells based on flow cytometric analysis. p values, unpaired Student’s t-test. 
Data are representative of three independent experiments. NS, not significant 
 
Because CD4+ T cells are the primary producers of IL-4 in Ndfip1-/- mice, we attempted 
to generate mice lacking CD4+ T cells by crossing Ndfip1-/- mice to mice lacking all 
conventional MHC class II genes (MHCII-/- mice). Surprisingly, we observed that Ndfip1-/- 
MHCII-/- CD8+ T cells had a phenotype similar to Ndfip1-/- CD8+ T cells (Figure 11 A-B; 
Figure 8 A-B). MHCII-/- mice have previously been described as containing a small 
percentage of mature peripheral CD4+ T cells which may be selected on 
nonconventional MHC molecules (208). We analyzed splenocytes from Ndfip1-/- MHCII-/- 
mice and confirmed that ~2-3% of lymphocytes were CD4+ T cells (Figure 11). Nearly 
100% of these cells were CD44hi (data not shown). To test the possibility that this small 
but apparently activated population of cells could be producing IL-4, we stimulated total 
splenocytes with anti-CD3 overnight and analyzed IL-4 secretion by ELISA. As 
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expected, neither WT nor control MHCII-/- cells produced detectable levels of IL-4, while 
Ndfip1-/- cells produced a great deal of this cytokine (Figure 11 D). Notably, although IL-4 
was greatly reduced in Ndfip1-/- MHCII-/- cells, it was still present at levels approximately 
50 times the limit of detection (Figure 11 D). To confirm that the small population of 
CD4+ cells in these mice was indeed producing IL-4, we analyzed intracellular cytokine 
production after stimulation with PMA and ionomycin. Ndfip1-/- MHCII-/- CD4+ cells were 
significantly more likely to be IL-4+ than control MHCII-/- CD4+ cells (Figure 11 E). Taken 
together, these data suggest that Ndfip1 restricts IL-4 production even in non-classical 
CD4+ T cells, and the IL-4 produced in Ndfip1-/- MHCII-/- mice is sufficient to induce a 
memory-like phenotype in CD8+ T cells. 
Ndfip1KO CD8+ T cells are IL-4-dependent virtual memory cells 
Ndfip1-/- CD8+ T cells displayed characteristics of both innate and VM CD8+ T cells in the 
previous experiments. One major difference between these two cells types is that VM 
cells typically arise in the periphery, while innate CD8+ T cells arise in thymus (162). To 
determine the origin of memory-phenotype Ndfip1-/- CD8+ T cells, we sacrificed mice 
shortly after birth and compared CD8+ T cells isolated from thymus and spleen. Because 
Ndfip1 inheritance is non-Mendelian (unpublished observations), in order to generate 
more knockouts we bred in Ndfip1+/- mice to Ndfip1-/- mice and used Ndfip1+/- littermates 
as controls. In Figure 12 A-B it is apparent that splenic CD8+ T cells in Ndfip1-/- mice 
begin to take on a memory phenotype as early as 8 days after birth. In contrast, Ndfip1-/- 
CD8 SP thymocytes do not display a memory phenotype even at 4 weeks of age. This is 
consistent with results of IL-4 ELISA (Figure 12 C) which indicate very little IL-4 
production in the thymus compared to spleen. Thus, it appears that both IL-4 production 
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and appearance of memory-phenotype CD8+ T cells occur primarily in the periphery, not 
the thymus, of Ndfip1-/- mice. 
 
Figure 11: Ndfip1KO mice lacking MHC Class II retain some IL4+ CD4+ T cells and memory-
phenotype CD8+ T cells. 
(A) Representative histograms of CD44, CD122, and Eomes expression on splenic MHCIIKO and Ndfip1KO 
MHCIIKO (DKO) CD8+ T cells. (B) CD44, CD122, and Eomes expression on splenic MHCIIKO and DKO 
CD8+ T cells based on flow cytometric analysis. (C) CD4+ cells as a percentage of total lymphocytes in the 
spleen. (D) IL-4 ELISA on culture supernatants harvested from splenocytes stimulated overnight with anti-
CD3. (E) IL-4+ cells as a percentage of total CD4+ T cells after stimulation with PMA and ionomycin for 4 hrs. 
p values, unpaired Student’s t-test. Data are representative of two independent experiments. NS, not 
significant 
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Figure 12: Memory-like phenotype in Ndfip1-/-
CD8+ T cells first arises in the periphery. 
(A) Representative histograms of CD44 
expression on CD8+ T cells from spleen and 
thymus in Ndfip1KO and control Ndfip1+/- mice 
at 5, 8, and 28 days old. (B) CD44, CD122, and 
CD124 expression on CD8+ T cells from spleen 
and thymus based on flow cytometric analysis. 
(C) Spleen and thymus cells were stimulated 4hr 
with PMA & ionomycin and culture supernatants 
were analyzed for IL-4 by ELISA. p values, 
unpaired Student’s t-test. Error bars = SEM. n = 
4-8 per timepoint. *, p < .05; **, p < .01; ***, p < 
.001 
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To distinguish VM cells from antigen-experienced memory cells, it is helpful to use 
tetramer staining to identify cells specific for nominal antigen in unimmunized mice. To 
do this, we stained Ndfip1-/- spleen and LN cells with SIINFEKL-H2Kb tetramer to identify 
endogenous OVA-specific CD8+ T cells. Tetramer+ CD8+ T cells from Ndfip1-/- mice 
displayed elevated levels of CD44, CD122, CD124 and Eomes, and decreased 
expression of CD49d (Figure 13 A-B). This phenotype was absent in Ndfip1-/-IL4-/- cells 
(Figure 13 C-D). Thus, OVA-specific CD8+ T cells in naïve Ndfip1-/- mice have the same 
memory phenotype observed in bulk CD8+ T cells, and this phenotype is dependent on 
IL-4.  
The previous results establish that memory-phenotype Ndfip1-/- CD8+ T cells have the 
characteristics of VM cells. However, it was recently suggested that IL-4 plays a minor 
role in the development of the VM population of WT mice and that VM cells arise 
primarily in response to IL-15 (162). To determine whether IL-4 affected the VM cells in 
Ndfip1-/- mice, we examined the CD44hi CD49dlo VM cell population in WT and Ndfip1-/- 
mice and their IL-4-deficient counterparts. Consistent with previous findings (161, 162), 
we observed a small but significant decrease in the CD44hi CD49dlo VM cell population 
in IL-4-deficient mice compared to WT mice (Figure 14 A-B). Importantly, the majority of 
VM cells in Ndfip1-/- mice are absent in Ndfip1-/- IL-4-/- mice. When endogenous OVA-
specific CD8+ T cells were isolated from unimmunized mice, we again observed a large 
increase in CD44hi CD49dlo VM cells in Ndfip1-/- mice that was ablated in the absence of 
IL-4 (Figure 14 C). Together, this suggests that the VM cell population expands when 
exposed to increased IL-4 levels.  
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Figure 13: Memory-like phenotype in Ndfip1-/- CD8+ T cells is independent of nominal antigen 
exposure. 
(A) Representative histograms of CD44, CD122, CD124, Eomes, and CD49d expression on splenic WT and 
Ndfip1KO tetramer+ CD8+ T cells. (B) CD44, CD122, CD124, Eomes, and CD49d expression on splenic WT 
and Ndfip1KO tetramer+ CD8+ T cells based on flow cytometric analysis. (C) Representative histograms of 
CD44, CD122, CD124, Eomes, and CD49d expression on splenic IL4KO and DKO tetramer+ CD8+ T cells. 
(D) CD44, CD122, CD124, Eomes, and CD49d expression on splenic IL4KO and DKO tetramer+ CD8+ T 
cells based on flow cytometric analysis. p values, unpaired Student’s t-test. NS, not significant 
 
57 
 
Figure 14: Virtual memory cells in Ndfip1-/- mice are IL-4-dependent. 
(A) Representative contour plots of CD44 and CD49d expression on splenic WT, Ndfip1KO, IL4KO, and 
IL4KO Ndfip1KO (DKO) CD8+ T cells. (B) VM cells (CD44hi CD49dlo) as a percentage of total CD8+ T cells 
based on flow cytometric analysis. (C) VM cells (CD44hi CD49dlo) as a percentage of total tetramer+ CD8+ T 
cells based on flow cytometric analysis. p values, unpaired Student’s t-test. Data are representative of three 
independent experiments. 
 
Discussion 
Our data demonstrate that IL-4 in the periphery can lead to an expanded VM population. 
Although thymic IL-4 has a well-characterized role in the generation of innate CD8+ T 
cells, to our knowledge this is the first study to link overproduction of IL-4 to an increase 
in VM cells. Our data is consistent with recently published data (161, 162) showing that 
the naturally-occurring VM population in WT mice is decreased by ~20-30% in the 
absence of IL-4. One explanation for the comparatively minor role for IL-4 observed in 
those studies is that they primarily described VM cells in WT C57BL/6 mice, which have 
very low IL-4 levels. However, our data show that when IL-4 is produced at high levels in 
peripheral compartments, it is an important driver of VM cells.  
By establishing that high IL-4 levels can lead to increased VM cells, our data suggest a 
link between innate CD8+ T cells and VM cells. The primary differences that have been 
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described in these two memory-phenotype populations are their relative reliance on IL-4 
and their origins in the thymus vs. the periphery.  Both these differences may actually 
stem from differences in the experimental systems in which they were described. Unlike 
VM cells, innate CD8+ T cells have been described primarily in systems with elevated 
percentages of IL-4+ PLZF+ T cells. These IL-4+ PLZF+ T cells are, by and large, non-
conventional T cells that become activated in and localize to the thymus. In contrast, 
Ndfip1-/- mice have greatly increased IL-4 levels compared to WT mice, but the IL-4 is 
mostly produced by cells in the periphery. It is thus not surprising that the expansion of 
memory-phenotype CD8+ T cells in Ndfip1-/- mice occurs in the periphery in an IL-4-
dependent manner. This result suggests that innate CD8+ T cells and VM cells may not 
be fundamentally different cell types, but rather reflect different pathways leading to 
acquisition of the same phenotype. 
Cytokines and the generation of memory-phenotype cells 
It is possible that multiple cytokines contribute to the formation and maintenance of the 
normal VM population, as suggested by the consistent observation of loss of 20-30% of 
VM cells in IL-4KO or IL-4RαKO mice compared to WT B6 mice (161, 162) (Figure 14). 
Development of both VM cells and innate CD8+ T cells is dependent on Eomes, and the 
robust Eomes expression observed in both cell types may contribute to their ability to 
produce IFNγ (162, 191, 209). Sosinowski et al. point out that this links memory-
phenotype cells with IL-15, as IL-15 increases Eomes expression, which in turn 
increases CD122 expression and therefore sensitivity to IL-15 (38, 210). However, IL-4 
also induces Eomes expression in CD8+ T cells (36, 188, 211, 212), as does IL-2 (51). It 
seems likely, then, that exposure to sufficient quantities of IL-4 or IL-2 could initiate the 
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Eomes/CD122 feedback loop, propelling naïve CD8+ T cells towards a memory-like 
phenotype. 
Indeed, Sprent and Surh have suggested a general mechanism in which local high 
concentrations of common γ-chain cytokines, probably in concert with weak TCR 
stimulation by self-peptides and possibly aided by transient relief of inhibitory signals, 
cause naïve CD8+ T cells to acquire a memory phenotype (213). In addition to the 
cytokine dependence of VM and innate CD8+ T cells previously discussed, several other 
lines of evidence support this hypothesis. Enhanced IL-2, IL-15, or IL-7 signaling, either 
through transgenic overexpression or addition of cytokine-stabilizing molecules, leads to 
an expansion of memory phenotype CD8+ T cells in vivo similar to that observed in acute 
homeostatic proliferation (136, 156, 157, 214–217). In vitro, naïve human CD8+ T cells 
proliferate in the absence of antigen in response to either IL-7 or IL-15, and, at least 
upon IL-15 stimulation, acquire effector functions (218, 219). Naïve murine CD8+ T cells 
proliferate somewhat less efficiently when stimulated with IL-15 alone, but stimulation of 
with either IL-7 or IL-15 plus either IL-6 or IL-21 induces antigen-independent 
proliferation, upregulation of CD44 expression, and acquisition of IFNγ-secretion 
capacity (220, 221). Exposure to these cytokines in vitro also “primes” naïve CD8+ T 
cells, allowing them to proliferate and produce cytokines more effectively than unprimed 
cells in response to subsequent exposure to small amounts of anti-CD3 or cognate 
peptide (221, 222). In light of this, it seems probable that memory-phenotype CD8+ T 
cells can arise in response to localized increases in any of several cytokines. 
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The role of TCR signaling in cytokine-driven memory formation 
Although cytokine-driven generation of memory-like CD8+ T cells is usually independent 
of cognate antigen exposure, the TCR may still play an important role in the formation of 
alternative memory cells. TCR avidity for peptide/MHC complexes is well-known to 
influence acute homeostatic proliferation, such that naïve cells expressing transgenic 
TCRs with higher affinity for self-ligands proliferate more upon transfer to lymphopenic 
recipients than cells with lower-affinity TCRs (223). This is also true for proliferative 
responses to exogenous IL-15/IL-15α complexes (217). Additionally, among naïve CD8+ 
T cells with identical TCRs, higher affinity for MHC I conferred by increased CD8 
expression led to increased acute homeostatic proliferation (224). Just as TCR avidity 
can affect how well a cell responds to high levels of cytokine, exposure to cytokines can 
permit functional T-cell responses to otherwise suboptimal TCR stimulation (221, 222, 
225–227). Thus, it is likely that most antigen-independent T-cell responses represent 
some degree of synergy between cytokine stimulation and TCR stimulation by non-
cognate ligands. 
Signaling pathways in memory generation: STAT5 
If common γ-chain cytokines – at least IL-2, IL4, IL-15, and IL-7 – can induce naïve 
CD8+ T cells to acquire memory-like characteristics, they may well do so by activating a 
common signaling pathway. An obvious candidate to link these cytokines together with a 
downstream memory phenotype is STAT5. It is well-established that IL-2, IL-15, and IL-7 
all induce phosphorylation and activation of STAT5 (75, 228–230). Intriguingly, IL-4, 
although typically associated with STAT6 activation in naïve CD4+ T cells, can activate 
STAT5 in naïve and effector-differentiated CD8+ T cells as well as differentiated CD4+ T 
cells (231–234). It is notable that, in the studies described above which observed that IL-
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6 or IL-21 can synergize with IL-7 or IL-15 to enhance cytokine-induced phenotypic 
changes in T cells, addition of IL-6 or IL-21 enhanced STAT5 phosphorylation and 
binding to DNA in response to IL-7 or IL-15 (221). IL-6 or IL-21 alone did not stimulate 
proliferation, and induced low (IL-21) or no (IL-6) STAT5 phosphorylation observable by 
Western blot (221). Consistent with these in vitro experiments, transgenic mice 
expressing a constitutively active STAT5b gene have a greatly expanded population of 
memory-phenotype (CD44hi CD122+ CD25-) CD8+ T cells in vivo (235). The few naïve 
CD8+ T cells from these mice are able to undergo lymphopenia-induced homeostatic 
proliferation even in recipients lacking IL-7 and IL-15, unlike WT naïve CD8+ T cells 
(235). Similarly, when T cells were transduced with a constitutively active form of 
STAT5a and then transferred to LCMV-infected recipients, they exhibited both enhanced 
survival and enhanced proliferation compared to control cells and this resulted in a 
massively expanded memory cell population after viral clearance (236). STAT5 
activation is also a major mechanism by which IL-2 stabilizes the otherwise transient 
expression of genes initiated by weak TCR signaling, including genes for costimulatory 
receptors such as GITR, 4-1BB, and OX40 and effector proteins such as granzyme B 
(225). If a similar phenomenon occurs in vivo, it may suggest a mechanism by which 
cytokine and self-peptide ligands are able induce phenotypic changes in naïve CD8+ T 
cells.  
Signaling pathways in memory generation: Wnt 
Sosinowski et al. (162) suggest another signaling pathway likely to play a role in 
memory-phenotype acquisition: the Wnt/β-catenin pathway. One of the effector 
transcription factors associated with Wnt signaling is T-cell factor-1 (TCF-1). In the 
absence of TCF-1, few memory precursors develop upon infection, and those that do 
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become short-lived effector memory cells and fail to proliferate normally upon secondary 
infection (237–239). TCF-1 is important for optimal expression of Eomes, and restoration 
of Eomes levels partially corrects the defect in memory T-cell numbers (237). Transgenic 
mice expressing a constitutively active version of the p45 isoform of TCF-1 and a 
stabilized version of its transcriptional coactivator β-catenin developed more memory T 
cells in response to infection (240). Further, induction of the Wnt pathway during 
stimulation in vitro led naïve murine CD8+ T cells to become memory-like cells, rather 
than effector-phenotype cells (241). Similar experiments with human cells also led to 
arrested effector differentiation and expression of CD45RA rather than CD45RO, which 
could be corrected with addition of IL-15, IL-7, or IL-2 (242, 243). Transgenic 
overexpression of β-catenin led to an increase in memory-phenotype CD8 SP 
thymocytes and peripheral CD8+ T cells; however, most of this increase was ablated in T 
cells lacking IL-4Rα, suggesting that the majority of the effect on CD8+ T cells was due 
to the increased number of IL-4+ PLZF+ thymocytes also generated by enhanced β-
catenin expression (198). Sosinowski et al. make the observations that 1) at least one 
other TCF family member is known to bind to the Eomes promoter, 2) while the p45 
isoform of TCF-1 associates with β-catenin, the p33 isoform associates with the 
transcriptional repressor groucho and has generally inhibitory functions, and 3) TCF-
1KO mice have a CD8+ T cell compartment composed almost entirely of VM cells. This 
leads to the reasonable supposition that loss of TCF-1 results in abrogation of its 
inhibitory functions, but (and possibly because of this loss) other TCF family members 
are able to fulfill its activating role by promoting Eomes expression and memory 
differentiation.  
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Signaling pathways in memory generation: Convergence on PI3K/Akt 
Another signaling pathway that is associated with CD8+ T cell memory differentiation, the 
PI3K/Akt pathway, may actually serve as a link between STAT5 and Wnt/β-catenin 
signaling. When activated, phosphatidylinositol 3 kinase (PI3K) phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2), a phospholipid component of the plasma 
membrane, to phosphatidylinositol-3,4,5-trisphosphate (PIP3). The phosphatases PTEN 
and SHIP inhibit PI3K signaling by dephosphorylating PIP3 (244, 245). Proteins 
containing pleckstrin homology (PH) domains, such as Akt and PDK1, bind to PIP3 
(246). Binding to PIP3 activates PDK1 and induces a conformational change in Akt 
which makes Akt susceptible to phosphorylation and activation by PDK1 and mTorc2 
(247, 248). Once activated, Akt influences a large array of downstream targets to 
modulate various aspects of cell proliferation, metabolism, and differentiation. 
Importantly, Akt promotes Wnt signaling by phosphorylating glycogen synthase kinase 
3β (GSK3β), a negative regulator of β-catenin which is inactivated upon phosphorylation 
by Akt (249). Akt also indirectly activates mTOR signaling, and promotes the nuclear 
exclusion of FOXO transcription factors to diminish FOXO-dependent signaling (250).  
Akt signaling through the latter targets tends to promote effector rather than memory 
differentiation. FOXO1 induces transcription of IL-7Rα and KLF2, which in turn induces 
transcription of CD62L, S1P1 and CCR7 (251). These molecules are all characteristic of 
naive and central memory T cells, facilitating their survival as well as directing their 
localization to secondary lymphoid organs. Activation of Akt is required to inhibit this 
function of FOXO1 in effector CTLs, as inhibition of either Akt or PI3K function in CTLs 
induces re-expression of CD62L and CCR7 and greatly increased trafficking to lymph 
nodes (252). Further, when Akt is inhibited, naïve CD8+ T cells fail to acquire the 
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capacity to produce IFNγ, and effector CTLs lose the ability to do so; effector CTLs also 
exhibit greatly reduced expression of perforin, FasL, and several granzymes (252). Akt 
mediates effector differentiation largely through suppression of FOXO1 and activation of 
mTOR. FOXO1 represses effector differentiation in CD8+ T cells by suppressing T-bet 
expression and enhancing Eomes expression, skewing cells to a memory-like phenotype 
(253). Sustained mTORC1 activation by IL-12 enhances effector differentiation at the 
cost of memory differentiation by promoting T-bet expression (37, 254). This effect can 
be reversed, and memory differentiation enhanced, by treatment of CD8+ T cells with the 
mTOR inhibitor rapamycin. Activation of mTORC1 and inhibition of FOXO1 downstream 
of robust Akt activation is necessary for enhanced T-bet expression, reduced Eomes 
expression, and consequent effector differentiation (253). Further, enhanced memory 
differentiation in the presence of rapamycin requires expression of FOXO1 (253). In the 
absence of sustained Akt and mTORC1 signals, FOXO1 binds directly to the Eomes 
promoter to enhance Eomes expression (253). 
In their recent review on this topic and the associated study, Kim et al. present a model 
of effector vs. memory differentiation that ties together the literature on PI3K/Akt, 
mTORC1, FOXO proteins, and Wnt/β-catenin (250, 255). In this model, weak Akt 
signaling after T-cell activation promotes differentiation of memory CD8+ T cells through 
TCF-1 and β-catenin, while strong Akt signaling – representing the cumulative effect of 
antigen, costimulation, and/or cytokines – promotes terminal effector differentiation 
through mTORC1 activation. This is based on several observations. CD8+ T cells that 
express high levels of CD25 shortly after LCMV infection, which have previously been 
found to preferentially become SLECs rather than MPECs, display more phosphorylation 
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of Akt and mTOR (255). Constitutive activation of Akt led to increased phosphorylation of 
mTOR and a drastic impairment of memory development after LCMV infection (250).  
The inter-dependency of the pathways discussed can provide technical challenges to 
testing this model, and experiments must be designed and interpreted with care. For 
example, FOXO1 directly enhances expression of TCF-1 in Tregs, and potentially could 
do so in CD8+ T cells (256). This might explain why T cells expressing constitutively 
active Akt, which have high levels of mTOR activation and low FOXO1 activity, have low 
TCF-1 expression (255). Additionally, common methods of activating the Wnt pathway in 
vitro, such as the use of GSK3β inhibitors, also promote mTORC1 activity (257). 
Possibly for this reason, such experiments do not always replicate the enhancement in 
memory differentiation observed upon rapamycin treatment (242). 
How do common γ-chain cytokines fit in to this model? IL-2, IL-4, IL-7, IL-15 and IL-21 all 
activate PI3K/Akt signaling (212, 258–262). IL-7 stimulates PI3K signals through 
cytokine-induced phosphorylation of IL-7Rα, which directly associates with the p85 
regulatory domain of PI3K (263). CD122, the IL-2/IL-15Rβ chain, does not bind directly 
to p85 but instead binds to Shc, which binds to and promotes phosphorylation of Gab2, 
a scaffolding protein that binds to PI3K (264). IL-4 contributes to PI3K activation through 
its role in phosphorylating IRS proteins, which can then bind to p85 (265). Additionally, 
IL-4 signaling may induce phosphorylation and degradation of SHIP, thereby enhancing 
PI3K signaling (266). Notably, STAT5 also plays an important role in activating PI3K/Akt 
downstream of cytokine signaling. Constitutive activation of STAT5 promotes Akt 
activation, and this is dependent on STAT5 interaction with Gab2 and p85 (236, 267, 
268). This may explain the finding that STAT5 is required for Shc-induced Akt activation 
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upon IL-2 stimulation (269). STAT5 activation is also necessary for Akt activation and 
subsequent glucose uptake in T cells stimulated with IL-7 (270). Together, these data 
indicate that several of the common γ chain cytokines stimulate PI3K/Akt signaling, and 
they do so through STAT5-dependent and –independent mechanisms.  
We propose that a similar model could also account for generation of memory-like CD8+ 
T cells in the presence of cytokines. Under this model, basal IL-7 and IL-15 signaling 
and stimulation of the TCR by self-peptide ligands provide anti-apoptotic signals to naïve 
CD8+ T cells without inducing overt activation or proliferation, consistent with established 
mechanisms of homeostasis. However, increased IL-7, IL-15, IL-2, or IL-4, perhaps 
acting on T cells with slightly higher avidity TCRs or T cells experiencing reduced 
inhibitory signals, leads to weak or transient Akt signaling. This activation of Akt is 
insufficient to drive terminal effector differentiation, but promotes acquisition of a memory 
phenotype by activating Wnt/β-catenin signaling to increase Eomes expression.  
Concluding remarks 
It has been speculated that unconventional memory-phenotype CD8+ T cells may be 
important in early responses to infection (121, 213). However, our data suggests that 
these cells may be especially relevant in autoimmune or allergic disorders, which 
frequently involve increased local production of IL-4. Future research should address the 
question of whether memory-phenotype CD8+ T cells can be generated in a disease 
setting and, if so, whether they contribute to the pathology of inflammatory diseases. 
This topic will be explored further in the final chapter. 
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Materials and Methods 
Mice 
Ndfip1-/-, Ndfip1-/- IL4-/-, and Ndfip1fl/fl CD4-Cre+ mice have been described previously 
(89, 94, 206). MHCII-/- (B6.129S2-H2dlAb1-Ea/J) and CD45.1+ (C57BL6.SJL-Ptprca 
Pepcb/BoyJ) mice were purchased from The Jackson Laboratory. MHCII-/- mice were 
bred to Ndfip1+/- mice in our lab to generate MHCII-/- Ndfip1-/- mice. All mice were used at 
5-16 weeks of age unless otherwise noted. Ndfip1-/- mice were bred from heterozygous 
parents and WT littermates were used as controls, with the exception of data presented 
in Figure 3. For these experiments, mice were bred with one heterozygous and one KO 
parent; Ndfip1+/- littermates served as controls. In some cases, Ndfip1-/- mice were also 
Rag1+/-. No differences in T-cell phenotype were observed in Rag1+/- vs. Rag1+/+ mice. 
All mice were maintained in a barrier facility at the Children’s Hospital of Philadelphia. All 
animal experiments were approved and followed the guidelines set by the Institutional 
Animal Care and Use Committee at the Children’s Hospital of Philadelphia. 
Fetal-liver chimeras  
Livers were isolated from embryonic WT (CD45.1+) or Ndfip1-/- (CD45.2+) mice and 
single-cell suspensions were prepared by mashing through a 70μm filter. Cells were 
resuspended in freezing media (90% FCS, 10% DMSO) and kept at -80˚C until used. 
Thawed cells were resuspended in sterile PBS and injected i.v. into sub-lethally 
irradiated Rag1-/- recipients, ~5x105 cells/mouse. The chimeras were used in 
experiments six weeks later to allow reconstitution of the T cell compartment. 
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Antibodies and reagents 
The following fluorochrome-conjugated antibodies were purchased from Biolegend, 
eBioscience, or BD Pharmingen: anti-mouse CD3 (17A2), CD4 (RM4-5), CD8α (53–6.7), 
CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD49d (R1-2), CD122 (TM-β1 and 5H4), 
CD124 (mIL4R-M1), Eomes (Dan11mag), and IL-4 (11B11). Unlabeled anti-CD16/32 (Fc 
block, 2.4G2) was purchased from BD Pharmingen. SIINFEKL-H2Kb tetramer 
conjugated to Alexa Fluor 647 was obtained from the NIH Tetramer Facility. Dead cell 
staining was performed using Molecular Probes LIVE/DEAD Fixable Dead Cell Stain Kit 
(Invitrogen). 
Flow cytometry 
Single-cell suspensions of lymphocytes isolated from spleen or thymus were stained for 
10 min. on ice with live/dead stain, blocked for 5 min. with Fcblock, then stained a further 
25 min. with antibodies directed against surface antigens. Cells were then washed twice 
with PBS plus sodium azide plus FCS (FACS buffer). For tetramer staining, single-cell 
suspensions of combined spleen and lymph nodes were enriched for CD8+ T cells 
through negative selection using rat anti-mouse I-A/I-E (M5/114.15.2) and goat anti-rat 
IgG magnetic beads (New England Biolabs) according to the manufacturer’s protocol. 
Tetramer was added after blocking with Fcblock. Cells were then incubated on ice for 1 
hour, washed twice with FACS buffer and stained 25 min. for surface antigens. For 
intracellular cytokine staining, after surface staining cells were fixed for 20 min. on ice 
with BD CytoFix/CytoPerm and washed twice with 1X BD perm/wash buffer. Cells were 
then resuspended in perm/wash buffer plus antibodies directed against cytokines and 
stained on ice 1 hour. For intracellular transcription factor staining, after surface staining 
cells were fixed 1-16 hours with eBioscience Foxp3 fix/perm solution and washed twice 
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with 1X permeabilization buffer. Cells were then resuspended in FACS buffer plus 
antibodies directed against transcription factors and stained on ice 1 hour. Flow 
cytometry was performed on an LSRII or LSRFortessa (BD Biosciences) and results 
analyzed using Flow-Jo software (Treestar USA). Dead cells were excluded from 
analysis. For analysis of tetramer+ cells, tetramer+ gate was set using a fluorescence-
minus-one control that was stained for surface markers but not tetramer.  
ELISA 
Spleen cultures were set up at 1x106 cells/ml in complete DMEM and 5 mg/ml soluble 
anti-CD3 was used to activate T cells. Supernatants were collected at 22 h after 
stimulation and kept at -80˚C until used. ELISA was performed using the eBioscience 
Ready-Set-Go IL-4 kit according to the manufacturer’s instructions.  
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
What role might alternative memory cells play in normal hosts? 
As there is some evidence that the various types of memory-phenotype CD8+ T cells 
described in the previous chapter – HP memory cells, VM cells, innate CD8+ T cells – 
are generated primarily through cytokine exposure and weak TCR stimulation rather 
than activation by cognate antigen, Lee et al. collectively referred to these cells as 
“alternative” memory T cells and we will also do so in the remainder of this manuscript 
(121). Alternative memory cells arise naturally in mice, and probably also in humans 
(181, 188, 202). As researchers continue to describe these cells in more and more 
settings, the underlying mystery becomes more pressing: Why does alternative memory 
exist? What is the purpose of alternative memory cells? At the moment, all answers to 
these questions are largely speculative. Below, we first examine the various ways to 
study alternative memory cells, then discuss several possible rationales for their 
existence. 
Considerations in the study of alternative memory CD8+ T cells 
Alternative memory cells can prove challenging to study in vivo, especially when 
examining peripheral CD8+ T cells. Nevertheless, as the majority of alternative memory 
cells are found in the periphery, not the thymus, of WT mice (and presumably humans), 
it is worth developing techniques to probe their function.  
Alternative memory cells can be isolated from naïve mice by sorting for CD44hi CD122hi 
CD49lo (159, 162). Tetramer staining can be used to confirm TCR specificity for nominal 
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antigen. If larger numbers of antigen-specific alternative memory cells are required, the 
experiment becomes more difficult but still feasible. One can simply age naïve mice to 
increase the percentage of peripheral CD8+ T cells with a memory phenotype, but aging 
can have additional effects on lymphocytes and the immune system as a whole that may 
confound interpretation of results (116, 118, 160, 271). Likewise, administration of 
various cytokines including IL-2, IL-15, or IL-4 may increase alternative memory 
numbers, but will also affect other aspects of the immune system (121, 213). The best 
solution may be to use mice which express a transgenic TCR β chain derived from an 
OTI-specific TCR (Vβ5 Tg) on a Rag-sufficient background (167). This permits formation 
of polyclonal T cells through the endogenously rearranged TCR α chains, but leads to an 
increased population of cells specific to ova (~1-2% of peripheral CD8+ T cells). While 
the transgenic β chain may lead to other differences between the TCR repertoires of WT 
and Vβ5 Tg mice, the total numbers of CD8+ T cells and their overall phenotype, as well 
as the phenotype of OTI-specific CD8+ T cells, is the same in both WT and Vβ5 Tg mice. 
The apparently small impact of the transgenic β chain may be explained by experiments 
which suggest that the TCR α chain is a much more important determinant of antigen 
specificity than the β chain (272, 273). Once isolated, alternative memory cells can be 
used for in vitro studies to assess various functional parameters, or transferred to 
recipient mice for in vivo models of immune responses (discussed further in the next 
sections). 
An interesting option to follow alternative memory cells in vivo is presented by the 
Nur77GFP mice, which express GFP under the control of the Nr4a1 promoter (274). 
Originally developed to study the strength of TCR stimulation required to generate nTreg 
and iNKT cells, T cells from these mice express GFP upon TCR stimulation but not in 
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response to STAT5 signaling or inflammation induced by LPS or polyI:C. GFP 
expression in these cells is transient, with GFP MFI gradually decreasing over several 
days in the absence of TCR stimulation. Moreover, GFP MFI is proportional to ligand 
avidity, and even the weak TCR signaling induced by homeostatic interactions with self-
peptide ligands still elevates GFP expression above baseline. The potential to 
distinguish between CD44hi T cells which are experiencing minimal TCR stimulation from 
those responding to cognate antigen makes this mouse model especially appealing for 
the study of alternative memory. Initial experiments would be required to confirm the 
assumption that most CD49dlo CD44hi cells arise in the absence of strong TCR signals, 
and that cells assumed to be alternative memory cells – such as CD44hi CD122hi CD49lo 
cells specific for nominal antigens such as ovalbumin – express low or intermediate 
levels of GFP compared to conventional antigen-specific memory cells.  
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Figure 15: Possible in vivo roles for alternative memory CD8+ T cells 
Examples of possible functions for alternative memory CD8+ T cells in vivo. Note that these are not mutually 
exclusive. (1) Alternative memory cells can respond to IL-12 & IL-18 produced by innate cells by secreting 
IFNγ, which can help control pathogen spread early in primary infections until antigen-specific T-cell 
responses develop. (2) Under normal circumstances, proliferating antigen-specific T cells may consume 
many of the cytokines generated in response to pathogen infection. However, if there are insufficient 
antigen-specific precursors or antigen-specific cells are unable interact with ligand-loaded APCs, any of 
several cytokines may accumulate and drive generation of alternative memory cells which may help control 
pathogen load in an antigen-independent manner, possibly as described in (1). (3) Increased IL-4 during 
allergic responses such as asthma may lead to increased numbers of alternative memory CD8+ T cells. 
These cells may then help limit IL-4-mediated pathology by producing IFNγ to oppose IL-4 functions. (4) 
Increased IL-4 during allergic responses such as asthma may lead to increased numbers of alternative 
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memory CD8+ T cells. These cells may then remain in their original location or traffic to other organs; in 
either case, they may induce or contribute to pathology through direct cytotoxic tissue damage.  
 
Hypothesis 1: Alternative memory CD8+ T cells enhance early responses to 
primary infections 
Alternative memory CD8+ T cells, like conventional memory cells, are able to produce 
IFNγ rapidly in response to IL-12 and IL-18 with antigen stimulation. This is an important 
aspect of the early response to intracellular bacterial infections (168, 275, 276). Early 
response to infection has thus been an obvious focus for research into the potential role 
of alternative memory cells, which could theoretically help keep bacterial pathogens in 
check until antigen-specific responses develop (Figure 15). Indeed, alternative memory 
cells have been observed to reduce bacterial load during Listeria infection in many 
models (146, 156, 162, 167, 187, 188). However, these studies are typically performed 
by isolating alternative memory cells and transferring them to recipient mice prior to 
infection, or by otherwise altering the endogenous alternative memory population. Thus, 
while such experiments are useful to describe what alternative memory cells are able to 
do, they cannot shed light on what alternative memory cells actually do and whether they 
play a non-redundant role in the response to infection. 
To explore this question, it would be ideal to specifically delete alternative memory cells 
from the T-cell pool and determine whether immune responses to pathogens are 
impaired. However, there is currently no obvious way to selectively target these cells. 
Eomesodermin and IL-15 are both important for the development or maintenance of 
alternative memory cells, but deletion of either of these proteins would have many non-
specific effects. Eomes and IL-15 are both important for the generation of NKT cells and 
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tend to skew the phenotype of conventional T cells to central memory rather than 
effector memory. Additionally, IL-15 is the chief homeostatic cytokine for conventional 
memory CD8+ cells and NKT cells, and has a small role in the homeostasis of naïve 
CD8+ T cells as well. Without a clear way to distinguish alternative and conventional 
memory cells that permits deletion of the former, it will be difficult to establish the true 
role of alternative memory, a caveat that applies for all the hypotheses discussed here. 
Hypothesis 2: Alternative memory CD8+ T cells are a backup for inadequate 
conventional responses 
A variation of this idea has been applied specifically to HP memory cells ever since it 
was observed that lymphopenia can induce naïve T cells to acquire a memory-like 
phenotype. The idea is that homeostatic mechanisms, which normally force T cells to 
compete for survival signals, serve as a fail-safe to maximize the efficacy of existing T 
cells when their numbers fall too low. Taken more generally, alternative memory cells 
could be generated during any period of transient lymphopenia, such as that found in 
newborns or following certain infections or injuries, to shore up immune responses until 
T cells have sufficiently reconstituted (165, 277–281).  
How does this theory fit with data showing that cytokines not traditionally associated with 
homeostasis, such as IL-4 and IL-2, can also lead to increased memory-phenotype 
cells? To answer this, we must consider situations other than straightforward 
lymphopenia that might be associated with high levels of cytokine. Pathogen infections 
are well-known for inducing inflammatory cytokine production, but there is no reason to 
think that antigen-nonspecific T cells have substantial exposure to these cytokines 
compared to responding, proliferating antigen-specific cells, which typically make up the 
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bulk of the CD8+ T cell pool during the peak of infection and which are known to 
upregulate cytokine receptors such as CD25 (part of the high-affinity IL-2 receptor, along 
with CD122 and CD132) (282, 283). However, we can imagine that inflammatory 
cytokines may accumulate in cases where T cells specific for a particular antigen are 
missing from the T-cell pool (perhaps due to TCR repertoire alteration by endogenous 
viral superantigens), or where antigen-specific T cells are present but cannot find their 
cognate antigen (such as during infections by pathogens that induce downregulation of 
MHC I on APCs). If so, it is possible that these elevated cytokine levels serve to recruit 
antigen-nonspecific CD8+ T cells to the immune response by inducing a memory 
phenotype that includes increased effector cytokine production (Figure 15). 
One possible approach to further explore this idea would require mice with a known 
deficit in the T-cell repertoire. An example is mice lacking T cells which express the TCR 
Vβ5 chain, which is an important component of the OTI ova-specific TCR (284). If such 
mice were immunized with ovalbumin and an inflammatory adjuvant, such as CFA, it 
might be expected that they would generate more antigen-nonspecific memory-
phenotype CD8+ T cells than WT mice immunized the same way. Of course, even Vβ5-
deficient mice probably contain T cells with other ova-specific TCRs, and it would be 
important to distinguish endogenous, non-OTI ova-specific T cells responding 
conventionally to cognate antigen from true non-specific alternative memory T cells. 
While this could be accomplished in several ways, an ideal method would be to use the 
Nur77GFP mice described above. Analysis of GFP on CD44hi cells in WT Nur77GFP and 
Vβ5-deficient Nur77GFP mice after ova immunization could potentially differentiate T cells 
responding to cognate antigen stimulation from those responding to nonspecific 
inflammatory signals.  
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Hypothesis 3: Alternative memory CD8+ T cells are not an end in themselves 
The existence of alternative memory cells does not imply that they are essential, or 
important at all, to a healthy immune system. Evolution is not omnipotent; it does the 
best it can with what it has to work with, and the results are not always elegant, 
streamlined, or ideal. This is evidenced by the maintenance of alleles that will result in 
harm to a small population but help a larger one (285); by the continued existence of 
vestigial organs (286); and by the occasional reappearance of ancestral traits (287). It is 
therefore possible that alternative memory cells are more a quirk of biology than a useful 
component of the immune system. 
Alternative memory cells may be, for example, an evolutionary relic, a remnant of the 
early history of adaptive immunity. It may be that alternative memory CD8+ T cells once 
did play an important role in immune response – perhaps through the potential functions 
discussed above – but that, over time, conventional T-cell responses evolved to be more 
effective, better coordinated, or longer-lived, and there is no longer a need for alternative 
memory cells. Though this cannot be proved conclusively, to explore this hypothesis 
further it would be instructive to determine whether alternative memory cells also exist in 
lower vertebrates, and if so, whether they comprise a larger percentage of total T cells in 
these species than in mice. 
The mechanisms by which alternative memory CD8+ T cells appear to arise are known 
to be important to other aspects of immunity. Specifically, IL-7 and IL-15, along with 
weak TCR stimulation by self-peptide ligands, are important for T-cell homeostasis. The 
ability of IL-2 and other cytokines to act as costimulatory factors may augment T-cell 
responses to inflammatory stimuli. Together, these properties of the immune system 
78 
 
may result in the occasional generation of an alternative memory CD8+ T cell due to 
stochastic, localized cytokine increases. Under this view, alternative memory cells are 
essentially a byproduct of processes that primarily function to promote T-cell 
homeostasis. Of course, we can never be sure that a biological phenomenon evolved 
solely as a byproduct of something else rather than based on its own merits, just as we 
can never really know “why” anything evolved as it did. All we can do is look for 
satisfying explanations.  
It’s important to note that, even if alternative memory is unimportant for normal immune 
responses, its study may still be worthwhile. First, because conventional and alternative 
memory cells are nearly indistinguishable, characterizing the latter may improve our 
understanding of the former. Second, as anyone with appendicitis can attest to, some 
aspects of our biology are mostly dispensable when functioning normally but, under the 
right conditions, can be the source of serious morbidity. In the next section, we discuss 
this potential aspect of alternative memory T cells. 
What role might alternative memory cells play in disease? 
Alternative memory CD8+ T cells and IBD 
Inflammatory bowel disease is characterized by chronic inflammation and immune 
disregulation in the gastrointestinal tract (91). Although often thought of as driven 
primarily by CD4+ T cells, IBD can also be induced by CD8+ T cells in mouse models 
(288, 289). A common method to induce colitis experimentally involves the transfer of 
either naïve CD4+ or naïve CD8+ T cells into lymphopenic mice, typically mice lacking 
Rag1 or Rag2. After transfer, both types of T cells undergo rapid spontaneous 
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proliferation that is dependent on IL-6 and an intact microbiota (288, 290). However, it 
may possible for elevated levels of cytokines such as IL-2 or IL-4 to substitute for 
microbial stimulation. Thus, in mice with intrinsic defects in cytokine production, such as 
Ndfip1KO mice, T cells may require little stimulation from foreign antigen to take on a 
memory phenotype. Such a possible effect of increased IL-4 may explain the inability of 
antibiotic treatment to reduce T-cell activation and intestinal pathology in our study 
(Chapter 2). This hypothesis could be tested by attempting to block IL-4 in vivo with 
antibody in Ndfip1 cKO mice with or without concurrent antibiotic treatment. As the 
balance of intestinal cytokines is an important factor in the pathology of IBD (291), it 
would also be interesting to test this hypothesis in IL-10 deficient mice, which develop 
spontaneous colitis unless treated with antibiotics or raised in germ-free housing (97). If 
germ-free IL-10KO mice given exogenous IL-4 develop colitis, it would suggest that 
sufficient inflammatory cytokine levels can drive IBD pathology even with minimal 
microbial stimulation, possibly through spontaneous proliferation of colitogenic T cells. 
This may explain the epidemiological finding that IBD and asthma, a disease typically 
characterized by increased IL-4+ T cells, are often co-morbid (292–294) (Figure 15). 
In addition to directly promoting an increase in memory-phenotype cells, common γ 
chain cytokines may contribute to IBD by promoting increased IL-6 production, which is 
a common feature in IBD (291). Mice with a truncated form of the common γ chain 
receptor spontaneously develop colitis driven by IL-6+ T cells; loss of this receptor has 
been observed to lead to increased IL-2 and IL-15 levels (155, 295). IL-4 can induce IL-6 
production in keratinocytes, and we have observed an IL-4-dependent increase in serum 
IL-6 in Ndfip1KO mice (206, 296). Elevated levels of IL-6 may contribute to increased T-
cell activation (221).  
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CD8+ T cells may also contribute to IBD in humans. Patients with IBD have elevated 
percentages of peripheral CD4+ and CD8+ T cells with an activated phenotype (297). 
Peripheral CD8+ T cells isolated from patients with IBD are significantly more likely to 
produce IFNγ in response to stimulation by co-culture with epithelial cells than T cells 
from healthy controls (298). This was not observed in CD4+ T cells and was dependent 
on MHC I. Whether this property of IBD-associated CD8+ T cells contributes to disease 
etiology or whether it arises as a byproduct of inflammation remains to be characterized. 
Additionally, CD8+ T cells from human patients with IBD can be divided based on 
transcriptional profiling into 2 subsets that are associated with different prognoses, with 
the subset expressing genes signatures associated with IL-2, IL-7, and TCR signaling 
being predictive of more severe or persistent IBD  (299). Further, this transcriptional 
signature was extremely similar to that observed in CD8+ T cells from patients with 
autoimmune disease (300). 
Alternative memory CD8+ T cells and allergy 
As discussed in Chapter 1, IL-4 plays an important role in establishing and maintaining 
pathological responses in many examples of allergy. One can imagine two potential 
roles for alternative memory CD8+ T cells in allergy: first, they might contribute to 
pathology, possibly through direct tissue damage by nonspecific cytotoxic activity. 
Second, these T cells might instead help mitigate disease, perhaps by production of 
IFNγ (Figure 15). Evidence exists for both possibilities.  
In mouse models of allergic airway disease, CD8+ T cells that develop in the presence of 
IL-4+ CD4+ cells worsen lung pathology (301, 302). Additionally, increased bronchial 
CD8+ cell infiltrate in human asthma patients is predictive of decreased lung function 
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(303). Moreover, CD8+ T cells are involved in some types of allergic contact dermatitis 
and cause apoptosis of skin cells (17, 304–306). A subset of these CTLs found in nickel 
allergies can lyse nickel-containing cells independent of MHC interactions (307, 308). To 
test the ability of alternative memory to mediate allergic reactions such as contact 
dermatitis, alternative memory CD8+ T cells could be transferred to recipients who are 
then sensitized and challenged with allergen. As discussed previously, such experiments 
may establish sufficiency but not necessity; without a method for specifically depleting 
these cells, it is difficult to determine whether alternative memory cells are necessary for 
the development of the allergic reactions in vivo.  
A role for CD8+ T cells in inhibiting allergic responses has also been observed. In 
asthma models, although CD8+ T cells can contribute to pathology, it has been 
suggested that this may be due to Tc2-polarized IL-13+ CD8+ T cells and that Tc1-
polarized CD8+ T cells may actually ameliorate disease (309–311). Remarkably, there is 
already indirect evidence that alternative memory CD8+ T cells can mediate this 
protection. Mice which transgenically overexpress IL-15 have an increased memory-like 
CD8+ T-cell population, and these T cells were necessary and sufficient to suppress 
eosinophilia and Th2-type cytokine production (312). A similar finding is observed in 
adult mice that had been immunized shortly after birth with semi-allogeneic dendritic 
cells (302). TCR transgenic CD8+ T cells activated in vitro, then transferred to mice 
intranasally, were able to prevent airway eosinophilia in a model of airway inflammation 
through antigen-nonspecific IFNγ production (313). Thus, it is possible that alternative 
memory cells which develop due to allergy-induced IL-4 may actually serve to limit the 
extent of pathology.  
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Concluding remarks 
In this work, we have examined the influence of two external factors, intestinal bacteria 
and IL-4, on the phenotype of CD8+ T cells. We conclude that IL-4, but not gut bacteria, 
is necessary for the increase in memory-phenotype CD8+ T cells in Ndfip1-deficient 
mice. We have discussed the potential implications of this finding for the role of CD8+ T 
cells in health and disease. Our work has reinforced the idea that excess production of a 
single cytokine can have manifold effects on the immune system and the health of the 
host.  
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